CURRICULUM VITAE

Roderick H. Dashwood, B.Sc., M.Sc., Ph.D., FRSB

POSITION	Director, Center for Epigenetics & Disease Prevention; University Distinguished Professor, Department of Translational Medical Sciences, Texas A&M School of Medicine; John S. Dunn Chair in Disease Prevention, Texas A&M HEALTH.
ADDRESS	Texas A&M Health and Texas A&M School of Medicine (Houston campus), 2121 W. Holcombe Blvd., Houston, Texas 77030.
EDUCATION	
1982	BS (1st class Honors) Biological Sciences, specializing in Cellular Toxicology/Immunology, University of Plymouth, UK.
1983	MS Toxicology, Surrey University, UK.
1986	PhD Genetic Toxicology, University of Portsmouth, UK.



PROFESSIONAL EXPERIENCE

1986-1990	Post-doctoral Research Associate, Department of Food Science and Technology, Oregon State University, Corvallis, OR.
1990-1995	Assistant Professor, Department of Environmental Biochemistry, University of Hawai‘i at Mānoa, Honolulu, HI.
1995-1998	Associate Professor, Department of Environmental Biochemistry, University of Hawai‘i at Mānoa, Honolulu, HI.
1997-1998	Foreign Research Fellow, National Cancer Center, Chuo-ku, Tokyo, Japan.
1998-2002	Associate Professor, Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR.
1998-2013	Principal Investigator, Linus Pauling Institute, Oregon State University.
2001-2013	Member, National Institute of Environmental Health Sciences (NIEHS) Environmental Health Sciences Center, Oregon State University, Corvallis OR.
2002-2006	Leader, Environmental Mutagenesis & Carcinogenesis Research Core, NIEHS Environmental Health Sciences Center, Oregon State University.
2002-2013	Director, Cancer Chemoprotection Program, Linus Pauling Institute.
2002-2013	Professor, Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR.
2007-2008	Foreign Research Fellow, National Cancer Center, Tokyo, Japan.
2010-2013	*Helen P. Rumbel Professor for Cancer Prevention*.
2013-	Director, Center for Epigenetics & Disease Prevention, Texas A&M University, Institute of Biosciences & Technology, Houston, TX.

2013-2020 Professor, Department of Nutrition, Texas A&M University, College Station, TX.

2014-2019 Professor, Department of Molecular & Cellular Medicine, Texas A&M University College of Medicine, College Station, TX.

2014-2017 Member, Center for Translational Environmental Health Research, Texas A&M University Health Science Center, and Baylor College of Medicine.

2014-2017 Member, Texas A&M AgriLife Research, Vegetable & Fruit Improvement Center, College Station, TX.

2014- Adjunct Professor, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.

2014- Member, Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX.

2015- *John S. Dunn Chair in Disease Prevention*.

2016- IBT Director's Advisory Committee (DAC).

2016-2020 Advisory Board of the American Medical Professionals Foundation.

2016 National Cancer Institute (NCI) PREVENT External Steering Panel.

2016- NCI Board of Scientific Advisors (Working Group of External Experts).

2017- NCI PREVENT Program, Scientific Review Panel.

2017 Chair, ZRG1 EMNR-A (07) Grant Review Panel.

2017 Senior Member, Cancer Epigenetics Society.

2017 Fellow of the Royal Society of Biology (London).

2017-2018 Co-chair, Texas A&M College of Medicine Faculty Pay Plan Committee.

2018-2022 NIH Cancer Prevention Study Section (CPSS), standing member.

2020-2022 Chair, NIH Cancer Prevention Study Section.

2020 Professor, Department of Translational Medical Sciences, Texas A&M School of Medicine (Houston campus), 2121 W. Holcombe Blvd., Houston, TX 77025.

2023 University Distinguished Professor, Texas A&M School of Medicine.

PROFESSIONAL HONORS

1995 Regents' Medal for Excellence in Teaching (University of Hawai'i at Mānoa)
1997 Regents' Medal for Excellence in Research (University of Hawai'i at Mānoa)
1997-1998 Foundation for Promotion of Cancer Research Fellowships (Tokyo, Japan)
2007-2008 Foundation for Promotion of Cancer Research Fellowships (Tokyo, Japan)

2011-2013 Endowed Helen P. Rumbel Professor for Cancer Prevention
2013-2018 Texas A&M University Chancellor's Research Initiative (CRI) Awardee
2014 Rice University Institute of Biosciences & Bioengineering Medical Innovation Award
2015 John S. Dunn Chair in Disease Prevention (Texas A&M Health)
2017 Elected as *Fellow* of the Royal Society of Biology (London)
2018 NIH Chemoprevention Study Section – standing member
2020 Elected Chair of NIH Cancer Prevention Study Section
2022 "World's Top 2% Scientists", most-cited authors across all fields (Stanford)
2023 Texas A&M University Distinguished Professor

EDITORIAL BOARDS

2004-2007 *Exp Biol Medicine (Maywood)*
2004-2016 *Mutat Res/Reviews in Mutat Res*
2008-2016 *Pharmacol Res*
2010-2017 *Clin Epigenetics* (Associate Editor)
2010-2018 *Mol Carcinog* (Associate Editor)
2015-2021 *Cancer Prev Res (Phila)*
2020-2023 *Cancers* (*Basel)*
2020- *Cancer Science* (Associate Editor)
2020- *J Cancer Prev*

EXPERTISE

Cancer interception, multi-omics, gut microbiome, immunoepigenetics (deacetylase inhibition; noncoding RNA; DNA methylation; chromatin remodeling); β-catenin/Wnt signaling; preclinical models of colorectal cancer; human translational studies and clinical trials.

INVITED SEMINARS/TALKS (since full professor)

2003 "Impact of phytochemicals on β-catenin in mouse models of GI polyposis, and in rats initiated with heterocyclic amines", International Conference on Impact of the Environment on Colon Cancer, May 14-16, Miami, Florida.

2003 "Tumor suppressing effects of antioxidants from tea", NCI Workshop "Free Radicals: The Pros and Cons of Antioxidants", June 26-27, NIH Campus, Bethesda, Maryland.

2003 "Mechanisms of antimutagenesis and anticarcinogenesis by white tea", 8th International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis, October 4-8, Pisa, Italy.

2004 "Histone deacetylase inhibition by metabolites of sulforaphane", 95th Annual Meeting of the American Association for Cancer Research (AACR), March 27-31, Orlando, Florida.

2004 "Tea and cancer chemoprevention", 18th Annual Update for Dietitians, May 14, Salem Hospital, Oregon.

2004 "Chlorophyllin: anticarcinogen or tumor promoter in the colon", American Institute for Cancer Research/World Cancer Research Foundation Conference on Food, Nutrition, and Cancer, July 15-16, Washington, D.C.

2004 "Cancer chemoprevention studies with white tea", Niigata Congress on Functional Foods for Prevention and Treatment of Lifestyle and Age-Related Diseases", September 26-27, Niigata, Japan.

2004 "Chlorophyllin: anticarcinogen or tumor promoter of colon cancer?", Niigata University of Pharmacy and Analytical Food Sciences", September 28, Niigata, Japan.

2004 "Chemoprevention studies with chlorophyllin and chlorophyll-rich *Angelica keiskei*, *Oenanthe javanica* and *Brassica oleracea*", Current Prospects of Functional and Medicinal Food, November 17-19, Jeju Island, South Korea.

2005 "*In vivo* inhibition of histone deacetylase by sulforaphane", 96th Annual Meeting of the AACR, April 16-20, Anaheim, California.

2005 "HDAC as a novel target for chemoprevention: sulforaphane and other dietary agents", 9th International Conference on Environmental Mutagens, "Global Issues in Genetic Toxicology & Environmental Mutagenesis", Symposium on Anti-mutagens & Prospects for Chemoprevention, September 3-8, San Francisco, California.

2005 "Dietary agents as HDAC inhibitors", Targeting Carcinogenesis: Transduction, Transcription, Translation, October 7, Mayo Clinic and University of Minnesota Hormel Institute, October 6-7, Rochester, Minnesota.

2005 "Dietary HDAC inhibitors: time to rethink weak ligands in cancer prevention?", University of California at Davis Cancer Center, December 8, Davis, California.

2006 "Effects of white tea, caffeine, and EGCG on PhIP-induced tumorigenesis and β-catenin expression", 12th Annual Meeting of the Oxygen Club of California, Oxidants and Antioxidants in Biology, March 15-18, Santa Barbara, California.

2006 "Can kangkung conquer cancer? Chemoprevention studies with chlorophyllin, chlorophyll, and chlorophyll-rich foods", Universiti Kabangsaan Malaysia, Medicine and Molecular Biology Institute, June 26, Kuala Lumpur, Malaysia.

2006 "Effects of white tea, caffeine, and epigallocatechin-3-gallate on PhIP-induced tumorigenesis and β-catenin expression", Cancer Prevention in the 21st Century, Universiti Putra Malaysia, June 27, Serdang, Malaysia.

2006 "HDAC inhibition: the next horizon for dietary cancer prevention?" 6th COSTAM/SFRR International Workshop on Micronutrients, Oxidative Stress, and the Environment, June 29-July 2, Kuching, Sarawak, Malaysia.

2006 "Targeting the epigenome with dietary chemopreventive agents, combined with inhibitors of Wnt signaling", National Research Laboratory of Molecular Carcinogenesis and Chemoprevention, College of Pharmacy, July 3, Seoul National University, South Korea.

2006 "Recent studies on the anticancer properties of chlorophylls", Ajou University Medical Center, July 5, Suwon, South Korea.

2006 "Frontiers in polyphenols and cancer prevention", AICR/WCRF International Research Conference on Food, Nutrition & Cancer, July 13-14, Washington, D.C.

2007 "Targeting the epigenome with dietary chemopreventive agents: sulforaphane as an inhibitor of histone deacetylase", Center for Molecular Medicine, University of Connecticut Health Center, March 7, Farmington, Connecticut.

2007 "Dietary HDAC inhibitors: from cells to mice to man", FASEB Summer Research Conference – Histone Deacetylases, June 2-7, Snowmass Village, Colorado.

2007 "Diet and its impact on genetic and epigenetic modulators of colon cancer", AAPS National Conference: Progress in Epigenetic Therapies, June 24-27, San Diego, California.

2007 "Diet and its impact on genetic and epigenetic modulators of cancer", 8th Congress of the International Society for Integrative Medicine, June 30-July 2, Tokyo, Japan.

2007 "Effects of white tea, caffeine, and EGCG on PhIP-induced tumorigenesis and β-catenin/T-cell factor signaling", 3rd International Conference on Polyphenols and Health, November 25-28, Kyoto, Japan.

2007 "Dietary anticarcinogens in the realm of epigenetics" International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis, December 1-5, Jeju Island, South Korea.

2007 "Dietary HDAC inhibitors: cells to mice to man", 2nd International Conference on Translational Cancer Research, December 9-12, Lonavala, India.

2008 "Diet and function of dietary HDAC inhibitors", American Institute for Cancer Research Conference – Food, Nutrition, Physical Activity, and Cancer, November 6-7, Washington, D.C.

2008 "Inhibition of HDAC activity by sulforaphane and garlic organosulfur compounds", 4th International Niigata Symposium on Diet and Health – Integrative Functions of Diet in Anti-aging and Cancer Prevention, November 28-30, Niigata, Japan.

2008 "Dietary histone deacetylase inhibitors", NIH/NIDDK Symposium Dynamic Epigenome and Homeostatic Regulations in Health and Disease, November 13-14, Bethesda, Maryland.

2009 "Epigenetics, diet, and disease", Linus Pauling Institute Diet and Optimum Health Conference, May 13-16, Portland, Oregon.

2009 "Epigenetics, diet, and cancer prevention", Toyo University, July 2, Kawagoe, Saitama, Japan.

2009 "α-Keto acid metabolites of organoselenium compounds inhibit HDAC activity", Workshop on Apoptosis: Mechanisms of Cell Death & Therapeutic Implications, Universiti Kabangsaan Malaysia, July 8, Kuala Lumpur, Malaysia.

2009 "NADPH oxidase 1 (NOX1) and NOX4 overexpression in colon cancer", COSTAM/SFRR Workshop, Chemoprevention and Translational Research, July 9-12, Pulau Langkawi, Malaysia.

2009 "α-Keto acid metabolites of organoselenium compounds inhibit HDAC activity", FASEB Summer Research Conference, Histone Deacetylases and Reversible Acetylation in Signaling and Disease, August 9-14, Lucca, Italy.

2009 "Dietary HDAC inhibitors: sulforaphane and organoselenium compounds", Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, August 19, Seattle, Washington.

2009 "Dietary histone deacetylase inhibitors: an epigenetic role for tea polyphenols?", 4th International Conference on Polyphenols and Health, December 7-11, Harrogate, United Kingdom.

2010 "Metabolism as a key to HDAC inhibition", American Society of Biochemistry and Molecular Biology Meeting, April 24-28, Anaheim, California.

2010 "Modification of histone acetylation by dietary compounds and role in cancer", 30th European Environmental Mutagen Society Meeting, September 15-18, Oslo, Norway.

2010 "HDAC inhibitors in colorectal cancer chemoprevention", AACR 9th Annual International Conference on Frontiers in Cancer Prevention Research, November 7-10, Philadelphia, Pennsylvania.

2011 "Role of metabolism in generating chemopreventive dietary HDAC inhibitors", International Conference on Nutrition and Physical Activity in Aging, Obesity, and Cancer, February 15-19, Gyeongju, South Korea.

2011 "HDAC turnover and recovery in sulforaphane treated colon cancer cells", National Cancer Center, February 23, Tokyo, Japan.

2011 "Metabolism as a key to HDAC inhibition", RIKEN Advanced Science Institute, February 25, Wako-shi, Japan.

2011 "Metabolism as a key to HDAC inhibition by chemopreventive agents", Medical University of South Carolina, April 21, Charleston, South Carolina.

2011 "Endothelins and their receptors in cancer: identification of therapeutic targets", 2nd International Scientific Meeting on Natural Products and Drug Discovery, King Saud University, May 1, Riyadh, Saudi Arabia.

2011 "Histone deacetylases as targets of dietary agents", 2nd International Scientific Meeting on Natural Products and Drug Discovery, King Saud University, May 2, Riyadh, Saudi Arabia.

2012 "What the heck did you just eat?! Messing with your epigenome", Partners in Science Annual Conference, January 14-15, San Diego, California.

2012 "Mechanistic studies of HDAC inhibition, turnover, and recovery", Human Nutrition Research Center, Tufts University, February 26, Boston, Massachusetts.

2012 “Role of metabolism in HDAC inhibition”, Laboratoire de Biologie Moleculaire et Cellulaire du Cancer, Hopital Kirchberg, March 8, Luxembourg.

2012 “HDAC turnover and recovery following exposure to dietary isothiocyanates”, Clinical Epigenetics Society, Homburg/Saar, March 9-10, Germany.

2012 “MicroRNAs, diet, and cancer”, Experimental Biology/American Society of Nutrition annual conference, April 21-25, San Diego, California.

2012 “PhIP, a cooked meat carcinogen, deregulates microRNA profiles in colon tumors”, Department of Food Science and Human Nutrition, October 11, University of Illinois-Champaign, Illinois.

2012 “Epigenetic trinity meets disease prevention”, Veterinary Medicine and Basic Science Program, University of Illinois College of Veterinary Medicine, October 12, Champaign, Illinois.

2013 “Mechanisms underlying bioactive food components and histone modifications”, Keystone Symposium on Nutrition, Epigenetics, and Human Disease, February 19-24, Santa Fe, New Mexico.

2013 “Epigenetic trinity and cancer prevention”, Institute of Biosciences and Technology, Texas A&M Health Science Center, March 18, Houston, Texas.

2013 “Dietary HDAC inhibitors: field to clinic”, University of Texas MD Anderson Cancer Center, April 23, Houston, Texas.

2013 “Dietary HDAC inhibitors: mechanisms to man”, Texas A&M University, College of Veterinary Medicine, April 25, College Station, Texas.

2013 “Epigenetic trinity meets nutrition”, 10th Annual Nutrition & Health Conference, May 13-15, Seattle, Washington.

2013 “Chemoprotective diets operating through miRNA: carcinogen *versus* inhibitor actions”, Marabou Symposium on Role of miRNA in Nutrition and Disease, June 14-16, Stockholm, Sweden.

2013 “Dietary KDAC inhibitors for cancer prevention and therapy”, December 5, Texas A&M University Kingsville, Texas.

2014 “What the heck did you just eat?! Messing with your epigenome”, Nutrition and Food Science Awards Banquet, April 9, College Station, Texas.

2014 “Epigenetics, diet, and cancer prevention”, May 5, Georgia Regents University Cancer Center, Augusta, Georgia.

2014 “Epigenetics, diet, and cancer prevention”, May 16, Center for Cancer Epigenetics, bi-monthly meeting, MD Anderson Cancer Center, Houston, Texas.

2014 “HDAC inhibitors and cancer chemoprevention”, May 20, University of Hawai‘i Cancer Center, Honolulu, Hawai‘i.

2014 “HDAC inhibitors and cancer chemoprevention”, 8th Annual Meeting of the Japanese Society for Epigenetics”, May 25-27, Tokyo, Japan.

2014 “Epigenetics, diet, and cancer prevention”, Clinical Science & Translational Research Grand Rounds, June 3, Bryan, Texas.

2014 “Epigenetics, diet and cancer prevention”, October 20, Department of Food and Nutrition, Sungshin Women’s University, Seoul, S. Korea.

2014 “Mechanistic and human translational studies in cancer chemoprevention”, October 23, College of Pharmacy, Seoul National University, Seoul, S. Korea.

2014 “Epigenetics, diet, and cancer prevention”, November 5, LaVell M. Henderson Lecture, University of Minnesota, St. Paul, Minnesota.

2015 “HDAC3 and Nrf2 affect antitumor outcomes with sulforaphane in the colon”, October 15, Department of Molecular and Cellular Medicine, Texas A&M College of Medicine, College Station, Texas.

2015 “Green with envy: cancer prevention by chlorophyll-rich foods”, November 2, Department of Nutrition and Food Science, Texas A&M University, College Station, Texas.

2017 “CCAR2 as a target for prevention of colorectal cancer”, Cancer Prevention & Control Grand Rounds, The University of Texas MD Anderson Cancer Center, Houston, TX, April 7, 2017.

2017 “Murine polypectomy and its utility in cancer prevention studies”, Digestive Diseases Center, Baylor College of Medicine, Houston, TX, April 20, 2017.

2017 “Murine polypectomy and its use in cancer prevention studies”. The University of Texas Health Science Center, Houston, TX, April 24, 2017.

2017 “Histone and non-histone targets of dietary deacetylase inhibitors”. University of Pittsburg School of Medicine, Pittsburg, PA, April 26, 2017.

2017 “CCAR2 as a target for early intervention in colorectal cancer”, Aspen Cancer Conference, Aspen, CO, July 15-18, 2017.

2017 “CCAR2 as a target for early intervention of colon cancer”, Dept. Pharmaceutical Sciences, Wayne State University, Detroit, MI, October 24-25, 2017.

2017 “CCAR2 as a target for early prevention of colon cancer”, Workshop on Next-gen Epigenomics, Baylor College of Medicine, Houston, TX, November 2, 2017.

2017 “Targeting epigenetic readers and erasers for cancer prevention”, National Cancer Center, Tokyo, Japan, November 20, 2017.

2018 “Targeting epigenetic readers and erasers for cancer prevention”, Inter-disciplinary Faculty of Toxicology, Texas A&M University, College Station, TX.

2018 “Targeting epigenetic readers/writers/erasers for cancer treatment”, RIKEN Yokohama, Yokohama, Japan, March 20-21, 2018.

2018 “Epigenetics-based approaches to cancer prevention using drug/diet combinations, Texas Academy of Nutrition & Dietetics, Tarrant County College, Arlington, TX, April 5, 2018.

2018 “Targeting epigenetic readers, writers and erasers for cancer treatment”, Cancer Seminar Series, The University of Texas at Austin, Austin, TX, April 25, 2018.

2018 “Targeting epigenetic readers/writers/erasers for cancer treatment”, Dept. Immunology, Hokkaido University, Sapporo, Japan, July 19-20, 2018.

2018 “Using precision nutrition to target epigenetic readers and erasers”, Seoul National University, Seoul, S. Korea, November 14, 2018.

2019 “Popeye’s microbiome; multi-omics approach to cancer prevention by spinach”, Center for Infectious & Inflammatory Diseases, Institute of Biosciences & Technology, Texas A&M College of Medicine, Houston, TX. March 4, 2019.

2019 “Multi-omics approach to cancer prevention by spinach”, Dept. Immunology, Hokkaido University School of Medicine, Sapporo, Japan. July 3, 2019.

2019 “Dietary analogs of sulforaphane synergize with JQ1 to inhibit colorectal cancer”, Tohoku University, Tohoku, Japan. July 29, 2019.

2019 “Epigenetics, diet, and cancer prevention”, Dept. Biology, Prairie View A&M University, Prairie View, Texas. October 3, 2019.

2019 “Optimizing dosing regimens of Erlotinib and Sulindac in a preclinical model of FAP”, MD Anderson Division of Pathology & Laboratory Medicine Grand Rounds. The University of Texas MD Anderson Cancer Center, Houston, TX. October 4, 2019.

2020 “Targeting epigenetic readers and erasers for colon cancer prevention”, Children’s Nutrition Research Center, Baylor College of Medicine, Houston, TX. November 5, 2020.

2021 “Targeting epigenetic readers and erasers for dietary cancer prevention”, NFSC681 Nutrition Seminar, Department of Nutrition, Texas A&M University, College Station, TX.

2021 “Cancer interception via next-generation bromodomain plus deacetylase inhibition”, Houston Methodist Hospital/Texas A&M Health Joint Seminar Series, Houston, TX, March 25, 2021.

2021 “Targeting epigenetic readers and erasers for cancer interception”, Istanbul University Genetics Club (IUGEN XVIII), Istanbul, Turkey, March 28, 2021.

2021 “Cancer interception via epigenetic readers/writers/erasers”, IBT Faculty Symposium, Houston, Texas, August 20, 2021.

2021 “Epigenetic modifiers for immunomodulation”, Translational Advances in Cancer Prevention Agent Development (TACPAD) Workshop, Division of Cancer Prevention, National Cancer Institute, September 13-14.

2021 “Cancer interception via next-generation deacetylase plus bromodomain inhibition”, Cancer Prevention and Control Grand Rounds, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021.

2022 “Cancer prevention by spinach: multi-omics to mechanisms”, invited webinar oral presentation, sponsored by the Chemoprevention and Nutritional Science Research Groups, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, March 10.

2022 “Immunoepigenetic targeting of MHC regulators in CRC”, University of Hawai‘i Cancer Center, Honolulu, HI, October 27, 2022.

2023 “Immunoepigenetic targeting of MHC regulators in Familial Polyposis”, Winship Elkin Lecture, Winship Cancer Institute of Emory University, Atlanta, GA. March 17, 2023. Atlanta Georgia.

2023 “Diet, Epigenetics, and Cancer Prevention”, Marshall University, Student Research Symposium, April 7-8, 2023, Huntington, WV. [Keynote speaker]

2023 “Cancer prevention strategies”, Foundations of Cancer Therapeutics, Bioscience Research Collaborative, Rice University, Houston, Texas, August 16, 2023.

PAPERS

1. Dashwood RH, Combes RD, Ashby J (1986) The disposition and *in vivo* covalent binding to liver DNA of the monoazo dyes 6-(*p*-dimethylaminophenylazo)benzothiazole (6BT) and 5-(*p*-dimethylaminophenylazo)indazole (5I) after administration to the rat. *Carcinogenesis* 7: 1029-33.
2. Dashwood RH, Combes RD, Ashby J (1986) Limitations of *in vitro* assays for distinguishing between a carcinogen/non-carcinogen pair of monoazo dyes. *Food Chem Toxicol* 24: 707-8.
3. Dashwood RH, Combes RD, Paton D, Ashby J (1986) Mutagenicity to *Salmonella* of four derivatives of the azo mutagen 5I: Some implications for structure-activity databases and the evaluation of combinations of mutagens. *Mutagenesis* 1: 261-5.
4. Dashwood RH, Combes RD (1987) Deficiencies in the covalent binding index (CBI) for expressing *in vivo* binding to DNA with respect to predicting chemical carcinogenicity: A proposal for a target-organ DNA binding index. *Mutat Res* 190: 173-5.
5. Dashwood RH, Combes RD, Ashby J (1987) Combined radiolabelling distribution and covalent DNA-binding studies to discriminate between a carcinogen/non-carcinogen pair of monoazo dyes related to the hepatocarcinogen Butter Yellow. *Arch Toxicol* S11: 99-101.
6. Dashwood RH, Combes RD (1987) Use of *in vivo*-like concentrations of chemicals for validation of *in vitro* short term genotoxicity assays: An *in vivo* equivalent dose concept. *Mutagenesis* 2: 249-51.
7. Dashwood RH, Combes RD, Ashby J (1988) DNA binding studies with 6BT and 5I: Implications for DNA binding/carcinogenicity and DNA binding/mutagenicity correlations. *Mutat Res* 198: 61-8.
8. Dashwood RH, Combes RD (1988) Levels of metabolic complexity in assays employing the *in vivo* equivalent dose (IVED) concept. *Mutagenesis* 3: 527-31.
9. Fong AT, Hendricks JD, Dashwood RH, Van Winkle S, Bailey GS (1988) Formation and persistence of ethylguanines in liver DNA of rainbow trout (*Salmo gairdneri*) treated with diethylnitrosamines by water exposure. *Food Chem Toxicol* 26: 699-704.

10. Fong AT, Hendricks JD, Dashwood RH, Van Winkle S, Lee BC, Bailey GS (1988) Modulation of DEN-induced hepatocarcinogenesis and O^6-ethylguanine formation in rainbow trout by indole-3-carbinol, β-naphthoflavone and aroclor 1254. *Toxicol Appl Pharm* 96: 93-100.
11. Dashwood RH, Arbogast D, Fong AT, Hendricks JD, Bailey GS (1988) Mechanisms of anti-carcinogenesis by indole-3-carbinol: Detailed in vivo DNA binding dose-response studies after dietary administration with AFB_1. *Carcinogenesis* 9: 427-32.
12. Dashwood RH, Arbogast DN, Fong AT, Pereira C, Hendricks JD, Bailey GS (1989) Quantitative interrelationships between AFB_1 carcinogen dose, indole-3-carbinol anti-carcinogen dose, target organ DNA adduction, and final tumor response. *Carcinogenesis* 10: 175-81.
13. Dashwood RH, Uyetake L, Fong AT, Hendricks JD, Bailey GS (1989) Synthesis of [^{3}H]-indole-3-carbinol, a natural anti-carcinogen from cruciferous vegetables. *J Label Compounds Radiopharm* 27: 901-8.
14. Dashwood RH, Uyetake L, Fong AT, Hendricks JD, Bailey GS (1989) *In vivo* disposition of the natural anti-carcinogen indole-3-carbinol after *p.o.* administration to rainbow trout. *Food Chem Toxicol* 27: 385-92.
15. Fong AT, Swanson HI, Dashwood RH, Williams DE, Hendricks J, Bailey GS (1990) Mechanisms of anticarcinogenesis by indole-3-carbinol: Studies of enzyme induction, electrophile-scavenging, and inhibition of aflatoxin B_1 activation. *Biochem Pharmacol* 39: 19-26.
16. Dashwood RH, Fong AT, Hendricks JD, Bailey GS (1990) Tumor dose-response studies with aflatoxin B_1 and the ambivalent modulator indole-3-carbinol: Inhibitory *versus* promotional potency. *Basic Life Sci* 52: 361-5.
17. Dashwood RH, Loveland PM, Fong AT, Hendricks JD, Bailey GS (1990) Combined in vivo DNA binding and tumor dose-response studies to investigate the molecular dosimetry concept. *Prog Clin Biol Res* 340D: 335-44.
18. Dashwood RH, Fong AT, Williams DE, Hendricks JD, Bailey GS (1990) Promotion of aflatoxin B_1 carcinogenesis by the natural modulator indole-3-carbinol (I3C): Influence of dose and intermittent exposure on I3C promotional potency. *Cancer Res* 51: 2362-5.
19. Dashwood R, Breinholt V, Bailey G (1991) Chemopreventive properties of chlorophyllin: Inhibition of aflatoxin B_1 (AFB_1)-DNA binding *in vivo* and anti-mutagenic activity against AFB_1 and two heterocyclic amines in the Salmonella mutagenicity assay. *Carcinogenesis* 12: 939-42.
20. Bailey GS, Dashwood RH, Fong AT, Scanlan RA, Hendricks JD (1991) Modulation of mycotoxin and nitrosamine carcinogenesis by I3C: Quantitative analysis of inhibition versus promotion. *IARC Sci Publ* 105: 275-80.
21. Bailey G, Hendricks J, Dashwood RH (1992) Anticarcinogenesis in fish. *Mutat Res* 267: 243-50.
22. Dashwood RH (1992) Protection by chlorophyllin against the covalent binding of 2-amino-3-methylimidazo[4,5-*f*]quinoline (IQ) to rat liver DNA. *Carcinogenesis* 13: 113-8.
23. Dashwood RH, Guo D (1992) Inhibition of 2-amino-3-methylimidazo[4,5-*f*]quinoline (IQ)-DNA binding by chlorophyllin: studies of enzyme inhibition and molecular complex formation. *Carcinogenesis* 13: 1121-6.
24. Dashwood R, Liew C (1992) Chlorophyllin-enhanced excretion of urinary and fecal mutagens in rats given 2-amino-3-methylimidazo[4,5-*f*]quinoline. *Environ Mol Mutagen* 20: 199-205.
25. Fong A, Dashwood RH, Cheng R, Mathews C, Hendricks J, Bailey G (1993) Carcinogenicity, metabolism, and Ki-*ras* proto-oncogene activation by 7,12-dimethybenz[*a*]anthracene in rainbow trout embryos. *Carcinogenesis* 14: 629-35.
26. Dashwood RH, Guo D (1993) Antimutagenic potency of chlorophyllin in the Salmonella assay and its correlation with binding constants of mutagen-inhibitor complexes. *Environ Mol Mutagen* 22: 164-71.

27. Guo D, Dashwood RH (1994) Inhibition of 2-amino-3-methylimidazo[4,5-*f*]quinoline (IQ)-DNA binding in rats given chlorophyllin: dose-response and time-course studies in the liver and colon. *Carcinogenesis* 15: 763-6.
28. Tachino N, Guo D, Dashwood WM, Yamane S, Larsen R, Dashwood RH (1994) Mechanisms of the *in vitro* antimutagenic action of chlorophyllin against benzo(*a*)pyrene: studies of enzyme inhibition, molecular complex formation, and degradation of the ultimate carcinogen. *Mutat Res* 308: 191-203.
29. Dashwood RH, Fong AT, Arbogast DN, Bjeldanes LF, Hendricks JD, Bailey GS (1994) Anticarcinogenic activity of indole-3-carbinol acid products: Ultrasensitive bioassay by trout embryo microinjection. *Cancer Res* 54: 3617-9.
30. Breinholt V, Schimerlik M, Dashwood RH, Bailey GS (1995) Mechanisms of chlorophyllin anticarcinogenesis against aflatoxin B_1: complex formation with the carcinogen. *Chem Res Toxicol* 8: 506-14.
31. Tachino N, Hayashi R, Liew C, Bailey GS, Dashwood R (1995) Evidence for *ras* gene mutation in 2-amino-3-methylimidazo[4,5-*f*]quinoline-induced colonic aberrant crypts in the rat. *Mol Carcinogen* 12: 187-92.
32. Takahashi N, Dashwood RH, Bjeldanes LF, Bailey GS, Williams DE (1995) Regulation of hepatic CYP1A1 by indole-3-carbinol: transient induction with continuous feeding in rainbow trout. *Food Chem Toxicol* 33: 111-20.
33. Guo D, Horio D, Grove J, Dashwood RH (1995) Inhibition by chlorophyllin of 2-amino-3-methylimidazo[4,5-*f*]quinoline (IQ)-induced tumorigenesis in the male F344 rat. *Cancer Lett* 95: 161-5.
34. Takahashi N, Dashwood RH, Bjeldanes LF, Williams DE, Bailey GS (1995) Mechanisms of indole-3-carbinol (I3C) anticarcinogenesis: inhibition of aflatoxin B_1 (AFB_1)-DNA adduction and mutagenesis by I3C acid condensation products. *Food Chem Toxicol* 33: 851-7.
35. Schut HAJ, Dashwood RH (1995) Inhibition of DNA adduct formation of 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP) by dietary indole-3-carbinol (I3C) in the mammary gland, colon and liver of the female F-344 rat. *Ann NY Acad Sci* 768: 210-4.
36. Guo D, Schut HAJ, Davis C, Snyderwine EG, Bailey G, Dashwood RH (1995) Protection by chlorophyllin and indole-3-carbinol against 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP)-induced DNA adducts and colonic aberrant crypts in the F344 rat. *Carcinogenesis* 16: 2931-7.
37. Liew C, Schut HAJ, Ching S, Pariza MW, Dashwood RH (1995) Protection of conjugated linoleic acids against 2-amino-3-methylimidazo[4,5-*f*]quinoline (IQ)-induced colon carcinogenesis in the F344 rat: A study of inhibitory mechanisms. *Carcinogenesis* 16: 3037-43. [Highly cited]
38. Dashwood RH, Yamane S, Larsen R (1996) A study of the forces stabilizing complexes between chlorophylls and heterocyclic amine mutagens. *Environ Mol Mutagen* 27: 211-8.
39. Xu M, Bailey AC, Hernaez JF, Taoka CR, Schut HAJ, Dashwood RH (1996) Protection by green tea, black tea, and indole-3-carbinol against colonic aberrant crypts induced in the rat by 2-amino-3-methylimidazo[4,5-*f*]quinoline. *Carcinogenesis* 17: 1429-34.
40. Hayashi R, Luk H, Horio D, Dashwood R (1996) Inhibition of apoptosis in colon tumors induced in the rat by 2-amino-3-methylimidazo[4,5-*f*]quinoline. *Cancer Res* 56: 4307-10.
41. Dashwood R (1997) Chlorophylls as anticarcinogens. *Int J Oncol* 10: 721-7.
42. Hasaniya N, Youn K, Xu M, Hernaez J, Dashwood R (1997) Inhibitory activity of green and black tea in a free radical-generating system using 2-amino-3-methylimidazo[4,5-*f*]quinoline as substrate. *Cancer Sci* 88: 553-8.
43. Hernaez J, Xu M, Dashwood RH (1997) Effects of tea and chlorophyllin on the mutagenicity of *N*-hydroxy-IQ: studies of enzyme inhibition, molecular complex formation and degradation/scavenging of the active metabolites. *Environ Mol Mutagen* 30: 468-74.
44. Xu M, Schut HAJ, Bjeldanes LF, Williams DE, Bailey GS, Dashwood RH (1997) Inhibition of 2-amino-3-methylimidazo[4,5-*f*]quinoline-DNA adducts by indole-3-carbinol: dose-response studies in the rat colon. *Carcinogenesis* 18: 2149-53.

45. Dashwood RH (1997) The importance of using pure chemicals in (anti)mutagenicity studies: chlorophyllin as a case in point. *Mutat Res* 381: 283-6.
46. Dashwood RH (1998) Indole-3-carbinol: anticarcinogen or tumor promoter in Brassica vegetables? *Chem-Biol Interact* 110: 1-5.
47. Dashwood RH, Suzui M, Nakagama H, Sugimura T, Nagao M (1998) High frequency of β-catenin (*Ctnnb1*) mutations in the colon tumors induced by two heterocyclic amines in the F344 rat. *Cancer Res* 58: 1127-9.
48. Hernaez J, Xu M, Dashwood RH (1998) Antimutagenic activity of tea towards 2-hydroxyamino-3-methylimidazo[4,5-*f*]quinoline: effect of tea concentration and brew time on electrophile-scavenging. *Mutat Res* 402:299-306.
49. Dashwood RH, Bailey GS (1998) Use of fish and fish transgenics in laboratory and field genotoxicology studies. *Mutat Res* 399: 123-4.
50. Bailey GS, Dashwood R, Loveland PM, Pereira C, Hendricks J (1998) Molecular dosimetry: quantitative target organ DNA adduction and hepatocarcinogenicity for four aflatoxins by dietary exposure. *Mutat Res* 399: 233-44.
51. Dashwood RH, Negishi T, Hayatsu H, Breinholt V, Hendricks JD, Bailey GS (1998) Chemopreventive properties of chlorophylls towards aflatoxin B_1: a review of the antimutagenicity and anticarcinogenicity data in rainbow trout. *Mutat Res* 399: 245-53.
52. Dashwood RH (1998) The Sufficiency Principle from the perspective of cancer prevention. *Jpn J Clinical Oncol* 28: 410-2.
53. Dashwood RH (1998) Cancer prevention from the food-borne carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine. *Mutat Res* 405: 109-10.
54. Hasaniya N, Razzuk A, Premaratne S, Zhang W, Abdul-Ghani A, Siera M, Dashwood RH, Eklof B, McNamara JJ (1998) Amelioration of ischemia/reperfusion injury in an isolated rabbit lung model using 2-ethyl-2,5,5'-trimethyl-3-oxazolidine. *Surg Forum* XLIX: 273-4.
55. Dashwood R (1999) Early detection and prevention of colorectal cancer. *Oncol Rep* 6: 277-81.
56. Dashwood RH, Xu M, Hernaez JF, Hasaniya N, Youn K, Razzuk A (1999) Cancer chemopreventive mechanisms of tea against heterocyclic amine mutagens from cooked meat. *Expl Biol Med* 220: 239-43.
57. Suzui M, Yoshimi N, Dashwood RH, Ushijima T, Sugimura T, Mori H, Nagao M (1999) Frequent mutations in the rat β-catenin gene (*Ctnnb1*) in the colon tumors induced by 1-hydroxyanthraquinone and methylazoxymethanol acetate. *Mol Carcinogen* 24: 232-7.
58. Xu M, Dashwood RH (1999) Chemoprevention studies of heterocyclic amine-induced colon carcinogenesis. *Cancer Lett* 143: 179-83.
59. Breinholt V, Arbogast D, Loveland P, Pereira C, Dashwood R, Hendricks J, Bailey G (1999) Chlorophyllin chemoprevention in trout initiated by aflatoxin B_1 bath treatment: an evaluation of reduced bioavailability *versus* target organ protective mechanisms. *Toxicol Appl Pharmacol* 158: 141-51.
60. Santana-Rios G, Dashwood RH (1999) Time to discontinue antigenotoxicity studies of dietary fiber? *Mutat Res* 429: 269-71.
61. Xu M, Chen R, Dashwood RH (1999) Effect of carcinogen dose fractionation, diet, and source of F344 rat on the induction of colonic aberrant crypts by 2-amino-3-methylimidazo[4,5-*f*]quinoline. *Carcinogenesis* 20: 2293-8.
62. Magnuson BA, South EH, Exon JH, Dashwood RH, Xu M, Hendrix K, Hubele S (2000) Increased susceptibility of adult rats to azoxymethane-induced aberrant crypt foci. *Cancer Lett* 161: 185-93.
63. Xu M, Orner GA, Bailey GS, Stoner GD, Horio HT, Dashwood RH (2001) Post-initiation effects of chlorophyllin and indole-3-carbinol in rats given 1,2-dimethylhydrazine or 2-amino-3-methylimidazo[4,5-*f*]quinoline. *Carcinogenesis* 22: 309-14.
64. Blum CA, Xu M, Orner GA, Fong AT, Bailey GS, Stoner GD, Horio DT, Dashwood RH (2001) β-catenin mutation in rat colon tumors initiated with 1,2-dimethylhydrazine or 2-amino-3-

methylimidazo[4,5-*f*]quinoline, and the effect of post-initiation treatment with chlorophyllin and indole-3-carbinol. *Carcinogenesis* 22: 315-20.
65. Dashwood RH, Xu M, Orner GA, Horio DT (2001) Colonic cell proliferation, apoptosis, and aberrant crypt development in rats given 2-amino-3-methylimidazo[4,5-*f*]quinoline and treated post-initiation with chlorophyllin. *Eur J Cancer Prev* 10: 139-45.
66. Yu Z, Xu M, Santana-Rios G, Shen R, Izquierdo-Pulido M, Williams DE, Dashwood RH (2001) A comparison of whole wheat, refined wheat, and wheat bran as inhibitors of heterocyclic amines in the *Salmonella* mutagenicity assay and in the rat colonic aberrant crypt focus assay. *Food Chem Toxicol* 39: 655-65.
67. Santana-Rios G, Orner GA, Amantana A, Provost C, Wu S, Dashwood RH (2001) Potent antimutagenic activity of white tea in comparison with green tea in the Salmonella assay. *Mutat Res* 495: 61-74.
68. Santana-Rios G, Orner GA, Xu M, Izquierdo-Pulido M, Dashwood, R.H. (2001) Inhibition by white tea of 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP)-induced colonic aberrant crypts in the F344 rat. *Nutr Cancer* 41: 98-103.
69. Li Q, Dixon BM, Al-Fageeh M, Blum CA, Dashwood RH (2002) Sequencing of the rat β-catenin gene (*Ctnnb1*) and mutational analysis of liver tumors induced by 2-amino-3-methylimidazo[4,5-*f*]quinoline. *Gene* 283: 255-62.
70. Franke AA, Custer LJ, Cooney RV, Tanaka Y, Xu M, Dashwood RH (2002) Inhibition of colonic aberrant crypt formation by the dietary flavonoids (+)-catechin and hesperidin. *Adv Expl Med Biol* 505:123-33.
71. Amantana A, Santana-Rios G, Butler JA, Xu M, Whanger PD, Dashwood RH (2002) Antimutagenic activity of selenium-enriched green tea towards the heterocyclic amine 2-amino-3-methylimidazo[4,5-*f*]quinoline. *Biol Trace Element Res* 86:177-91.
72. Dashwood RH (2002) Modulation of heterocyclic amine-induced mutagenicity and carcinogenicity: An 'A-to-Z' guide to chemopreventive agents, promoters, and transgenic models. *Mutat Res* 511: 89-112.
73. Dashwood RH (2002) White tea – a new cancer inhibitor. *Foods Food Ingred J* 200:19-26.
74. Dashwood WM, Orner GA, Dashwood RH (2002) Inhibition of β-catenin/Tcf activity by white tea, green tea, and epigallocatechin-3-gallate (EGCG): minor contribution of H_2O_2 at physiologically relevant EGCG concentrations. *Biochem Biophys Res Commun* 296: 584-8.
75. Orner GA, Dashwood WM, Blum CA, Díaz GD, Li Q, Al-Fageeh M, Tebbutt N, Heath JK, Ernst M, Dashwood RH (2002) Response of *Apc*^{min} and *A33*$^{\Delta N\beta\text{-cat}}$ mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP). *Mutat Res* 506-507:121-7.
76. Orner GA, Dashwood WM, Li Q, Al-Fageeh M, Tebbutt N, Heath JK, Ernst M, Dashwood RH (2002) Cellular effects of tea antioxidants in vitro and in mouse models of colorectal cancer: Modulation of Wnt signaling. *Free Radical Res* 36 (Suppl 1): 16-20.
77. Dashwood RH (2003) Use of transgenic and mutant animal models in the study of heterocyclic amine-induced mutagenesis and carcinogenesis. *J Biochem Mol Biol* 36: 35-42.
78. Blum CA, Orner G, Díaz GD, Li Q, Xu M, Dashwood WM, Bailey GS, Dashwood RH (2003) Promotion *versus* suppression of rat colon carcinogenesis by chlorophyllin and chlorophyll: Modulation of apoptosis, cell proliferation, and β-catenin/Tcf signaling. *Mutat Res* 523: 217-23.
79. Orner GA, Dashwood WM, Blum CA, Díaz D, Li Q, Dashwood RH (2003) Suppression of tumorigenesis in the *Apc*^{min} mouse: down-regulation of β-catenin signaling by a combination of tea plus sulindac. *Carcinogenesis* 24: 263-7.
80. Díaz D, Li Q, Dashwood RH (2003) Caspase-8 and AIF mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin. *Cancer Res* 63: 1254-61.
81. Blum CA, Tanaka T, Zhong X, Li Q, Dashwood WM, Pereira C, Xu M, Dashwood RH (2003) Mutational analysis of *Ctnnb1* and *Apc* in tumors from rats given 1,2-dimethylhydrazine or 2-

amino-3-methylimidazo[4,5-*f*]quinoline: Mutational 'hotspots' and the relative expression of β-catenin and c-Jun. *Mol Carcinog* 36: 195-203.
82. Dashwood RH, Xu M (2003) Disposition and metabolism of 2-amino-3-methylimidazo[4,5-*f*]quinoline in the rat at high *vs* low doses of indole-3-carbinol. *Food Chem Toxicol* 41: 1185-92.
83. Li Q, Dashwood WM, Al-Fageeh M, Zhong X, Dashwood RH (2004) Cloning of the rat β-catenin gene (*Ctnnb1*) promoter and its functional analysis compared with *Catnb* and *CTNNB1* promoters. *Genomics* 83: 231-42.
84. Mastaloudis A, Yu D, Frei B, Dashwood RH, Traber MG (2004) Gender differences in DNA damage generated during an ultramarathon run measured using the comet assay. *Free Rad Biol Med* 36: 966-75.
85. Al-Fageeh M, Li Q, Dashwood WM, Myzak MC, Dashwood RH (2004) Phosphorylation and ubiquitination of oncogenic mutants of β-catenin containing substitutions at Asp32. *Oncogene* 23:4839-46.
86. Dashwood RH (2004) Adherins junction remodeling: a novel target for cancer prevention and chemotherapy? *Int J Cancer Prev* 1: 15-18.
87. Li Q, Dashwood RH (2004) AP-2α associates with APC/β-catenin and inhibits β-catenin/TCF transcriptional activity in colorectal cancer cells. *J Biol Chem* 279: 45669-75.
88. Orner GA, Dashwood WM, Dashwood RH (2004) Tumor-suppressing effects of antioxidants from tea. *J Nutr* 134: 3177S-8S.
89. Yu TW, Xu M, Dashwood RH (2004) Antimutagenic activity of spearmint. *Environ Mol Mutagen* 44: 387-93.
90. Carter O, Bailey G, Dashwood RH (2004) The dietary phytochemical chlorophyllin alters E-cadherin and β–catenin expression in human colon cancer cells. *J Nutr* 134: 3441S-4S.
91. Myzak M, Karplus PA, Chung FL, Dashwood RH (2004) A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. *Cancer Res* 64:5767-74. [Highly cited]
92. Dashwood WM, Carter O, Al-Fageeh M, Li Q, Dashwood RH (2005) Lysosomal trafficking of β-catenin induced by the tea polyphenol epigallocatechin-3-gallate. *Mutat Res* 591: 161-72.
93. Dashwood RH, Myzak MC, Ho E (2006) Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? *Carcinogenesis* 27: 344-9. PMC2267878
94. Myzak MC, Dashwood RH (2006) Chemoprotection by sulforaphane: keep one eye beyond Keap1. *Cancer Lett* 233: 208-18. PMC2276573
95. Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E (2006) Sulforaphane inhibits HDAC activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. *Carcinogenesis* 27: 811-9. PMC2276576 [Highly cited]
96. Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH (2006) Sulforaphane inhibits histone deacetylase *in vivo* and suppresses tumorigenesis in *Apc*^{min} mice. *FASEB J* 20: 506-8. PMC2373266 [Highly cited]
97. Myzak MC, Dashwood RH (2006) Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide and sulforaphane. *Curr Drug Targets* 7: 443-52.
98. Orner GA, Roebuck BD, Dashwood RH, Bailey GS (2006) Post-initiation chlorophyllin exposure does not modulate aflatoxin-induced foci in the liver and colon of rats. *J Carcinogenesis* 5:6. PMC1373623
99. Zhen Y, Loehr CV, Fischer KA, Louderback MA, Krueger SK, Dashwood RH, Kerkvliet NI, Pereira CB, Jennings-Gee JE, Dance ST, Miller MS, Bailey GS, Williams DE (2006) In utero exposure of mice to dibenzo[*a,l*]pyrene produces lymphoma in the offspring: role of the aryl hydrocarbon receptor. *Cancer Res* 66: 755-62.
100. Myzak MC, Ho E, Dashwood RH (2006) Dietary agents as histone deacetylase inhibitors. *Mol Carcinog* 45: 443-6. PMC2267873
101. Dashwood RH (2006) Xenobiotic metabolism relevance to cancer. *J Nutr* 136: 2681S-2S

102. Cope RB, Loehr C, Dashwood R, Kerkvliet N (2006) Ultraviolet radiation-induced non-melanoma skin cancer in the Crl:SHK:hr-1 hairless mouse: augmentation of tumor multiplicity by chlorophyllin and protection by indole-3-carbinol. *Photochem Photobiol Sci* 5: 499-507.
103. Wang R, Dashwood WM, Bailey GS, Williams DE, Dashwood RH (2006) Tumors from rats given 1,2-dimethylhydrazine plus chlorophyllin or indole-3-carbinol contain transcriptional changes in β-catenin that are independent of β-catenin mutation status. *Mutat Res* 610: 11-18. PMC2279303
104. Kwon D, Yoon, S, Carter O, Bailey GS, Dashwood RH (2006) Antioxidant and antigenotoxic activities of *Angelica keiskei, Oenanthe javanica* and *Brassica oleracea* in the Salmonella mutagenicity assay and in HCT116 human colon cancer cells. *BioFactors* 26: 231-44.
105. Yu TW, Dashwood RH (2007) Measuring antigenotoxic effects using the Ames test and comet assay. *Am Biotechnol Lab* 25: 22-23.
106. Myzak MC, Hardin K, Tong P, Dashwood RH, Ho E (2007) Sulforaphane retards the growth of human PC-3 prostate cancer xenografts and inhibits HDAC activity in human subjects. *Expl Biol Med* 232: 227-34. PMC2267876 [Highly cited]
107. Dashwood RH (2007) Frontiers in polyphenols and cancer prevention. *J Nutr* 137: 267S-9S.
108. Higdon JV, Delage B, Williams DE, Dashwood RH (2007) Cruciferous vegetables and human cancer risk. *Pharmacol Res* 55: 224-36. PMC2737735 [Highly cited]
109. Carter O, Wang R, Dashwood WM, Orner G, Fischer K, Löhr C, Pereira C, Bailey GS, Williams DE, Dashwood RH (2007) Comparison of white tea, green tea, epigallocatechin-3-gallate and caffeine as inhibitors of PhIP-induced colonic aberrant crypts. *Nutr Cancer* 58, 60-5.
110. Simonich MT, Egner P, Roebuck WD, Orner GA, Jubert C, Pereira C, Groopman JD, Kensler TW, Dashwood RH, Williams DE, Bailey GS (2007) Natural chlorophyll inhibits aflatoxin B_1-induced multi-organ carcinogenesis in the rat. *Carcinogenesis*, 28: 1294-302.
111. Li Q, Dashwood WM, Zhong X, Nakagama H, Dashwood RH (2007) Bcl-2 over-expression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving β-catenin, c-myc and E2F1. *Oncogene* 26: 6194-202. PMC2267879
112. Dashwood RH, Ho E (2007) Dietary inhibitors of histone deacetylase: from cells to mice to man. *Semin Cancer Biol* 17: 363-9. PMC2737738
113. Simonich MT, McQuistan T, Jubert C, Mustafija-Jeknic T, Baird WM, Pereira C, Dashwood RH, Williams DE, Bailey GS (2008) Low-dose dietary chlorophyll inhibits multi-organ carcinogenesis in the rainbow trout. *Food Chem Toxicol* 46*:* 1014-24. PMC2404114
114. Dashwood RH, Ho E (2008) Dietary agents as histone deacetylase inhibitors: sulforaphane and structurally-related isothiocyanates. *Nutr Rev* 66: S36-8. PMC2656672
115. Wang R, Dashwood WM, Löhr CV, Fischer KA, Pereira CB, Louderback M, Nakagama H, Bailey GS, Williams DE, Dashwood RH (2008) Protective versus promotional effects of white tea and caffeine on PhIP-induced tumorigenesis and β-catenin expression in the rat. *Carcinogenesis* 29: 834-9. PMC2796682
116. Clarke J, Dashwood RH, Ho E (2008) Multi-targeted prevention of cancer by sulforaphane. *Cancer Lett* 269: 291-304. PMC2579766 [Highly cited]
117. Delage B, Dashwood RH (2008) Dietary manipulation of histone structure and function. *Ann Rev Nutr* 28: 347-66. PMC2737739
118. Castro DJ, Yu Z, Löhr CV, Pereira CB, Giovanini J, Fischer KA, Orner GA, Dashwood RH, Williams DE (2008) Chemoprevention of dibenzo[*a,l*]pyrene transplacental carcinogenesis in mice born to mothers administered green tea: primary role of caffeine. *Carcinogenesis* 29:1581-6. PMC2516488
119. Wang R, Dashwood WM, Löhr CV, Fischer KA, Nakagama H, Williams DE, Dashwood RH (2008) β-Catenin is strongly elevated in rat colonic mucosa following short-term intermittent treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine and a high-fat diet. *Cancer Sci* 99: 1754-9. PMC2775100

120. Nian H, Delage B, Pinto JT, Dashwood RH (2008) Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the *P21WAF1* promoter. *Carcinogenesis* 29: 1816-24. PMC2722850
121. Ashktorab H, Dashwood RH, Dashwood WM, Zaidi SI, Hewitt SM, Green WR, Lee E, Nouraie R, Malekzadeh R, Smoot DT (2008) *H. pylori*-induced apoptosis in human gastric cancer cells mediated via the release of AIF from mitochondria. *Helicobacter* 13: 506-17.
122. Castro DJ, Löhr CV, Fischer KA, Waters KM, Webb-Robertson BA, Dashwood RH, Bailey GS, Williams DE (2009) Identifying efficacious approaches to chemoprevention with chlorophyllin, purified chlorophylls, and freeze-dried spinach in a mouse model of transplacental carcinogenesis. *Carcinogenesis* 30: 315-20. PMC2722150
123. Nian H, Delage B, Ho E, Dashwood RH (2009) Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. *Environ Mol Mutagen* 50: 213-21. PMC2701665
124. Hasaniya H, Razzuk AM, Premaratne S, Zhang W, Abdul-Ghani AA, Siera M, Dashwood RH, Eklof B, Tinsley L, McNamara JJ (2009) Ischemia-reperfusion injury in the lung: quantitation using electron microscopy. *Vasc Endovasc Surg* 43: 170-7.
125. Li Q, Löhr CV, Dashwood RH (2009) Activator protein 2α suppresses intestinal tumorigenesis in the *Apc*^{min} mouse. *Cancer Lett* 28: 36-42. PMC2713803
126. Lee J, Nian H, Cooper A, Sinha R, Dai J, Bisson WH, Dashwood RH, Pinto JT (2009) α-Keto acid metabolites of naturally-occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. *Cancer Prev Res* 2: 683-93. PMC29022751
127. Nian H, Bisson WH, Dashwood WM, Pinto JT, Dashwood RH (2009) α-Keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. *Carcinogenesis* 30: 1416-23. PMC2718078
128. Chimploy K, Díaz GD, Li Q, Carter O, Dashwood WM, Mathews CK, Williams DE, Bailey GS, Dashwood RH (2009) E2F4 and ribonucleotide reductase mediate S-phase arrest in colon cancer cells treated with chlorophyllin. *Int J Cancer* 125: 2086-94. PMC2753276
129. Jubert C, Mata J, Bench G, Dashwood R, Tracewell W, Turteltaub K, Williams D, Bailey G (2009) Effects of chlorophyll and chlorophyllin on low-dose aflatoxin B1 pharmacokinetics in human volunteers: a pilot study. *Cancer Prev Res* 2: 983-93.
130. Ho E, Clarke JD, Dashwood RH (2009) Dietary sulforaphane, a dietary histone deacetylase inhibitor for cancer prevention. *J Nutr* 139: 2393-6. PMC2777483
131. Larsen CA, Dashwood RH (2009) Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: minor role of hydrogen peroxide. *Biochem Biophys Res Commun* 389: 527-30. PMC2761952
132. Larsen CA, Bisson WH, Dashwood RH (2009) Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies. *J Med Chem* 52: 6543-5. PMC2784189
133. Ashktorab H, Belgrave H, Hosseinkhah F, Brim H, Nouraie M, Takkikto M, Hewitt S, Lee EL, Dashwood RH, Smoot D (2009) Global Histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. *Digest Disease Sci* 54: 2109-17. PMC2737733
134. Ho E, Dashwood RH (2010) Dietary manipulation of histone structure and function. *J Nutrigenet Nutrigenomics* 3: 2321-8. PMC3085528
135. Kwon IK, Wang R, Thangaraju M, Shuang H, Liu K, Dashwood R, Dulin N, Ganapathy V, Browning DD (2010) PKG inhibits TCF signaling in colon cancer cells by blocking β-catenin expression and activating FOXO4. *Oncogene* 29: 3423-34. PMC3114416
136. Larsen CA, Dashwood RH (2010) (-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells. *Arch Biochem Biophys* 501:52-7. PMC2916072
137. Ho E, Dashwood RH (2010) Dietary manipulation of histone structure and function. *World Rev Nutr Diet* 101: 95-102. PMC3138488

138. Larsen CA, Dashwood RH, Bisson WH (2010) Tea catechins as inhibitors of receptor tyrosine kinases: mechanistic insights and human relevance. *Pharmacol Res* 62:457-64. PMC2974766
139. Hsu A, Bruno RS, Löhr CV, Taylor AW, Dashwood RH, Bray TM, Ho E (2011) Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFκB pathway in the Noble rat. *J Nutr Biochem* 22:502-10. PMC2995825
140. Wang R, Dashwood WM, Nian H, Löhr CV, Fischer KA, Tsuchiya N, Nakagama H, Ashktorab H, Dashwood RH (2011) NADPH oxidase expression in human colon cancers and rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP). *Int J Cancer* 128:2581-90. PMC3262595
141. Clarke JD, Hsu A, Yu Z, Dashwood RH, Ho E (2011) Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells. *Mol Nutr Food Res* 55:999-1009. PMC3129466
142. Wang R, Dashwood RH (2011) Endothelins and their receptors in cancer: identification of therapeutic targets. *Pharmacol Res* 63: 519-24. PMC3109221
143. Rajendran P, Williams DE, Ho E, Dashwood RH (2011) Metabolism as a key to histone deacetylase inhibition. *Crit Rev Biochem Mol Biol* 46:181-99. PMC3254183
144. Li Q, Luo C, Löhr CV, Dashwood RH (2011) Activator protein-2α functions as a master regulator of multiple transcription factors in mouse liver. *Hepatol Res* 41: 776-83.
145. Rajendran P, Delage B, Dashwood WM, Yu TW, Wuth B, Williams DE, Ho E, Dashwood RH (2011) Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. *Mol Cancer* 10:68. PMC3127849 [Highly accessed]
146. Clarke J, Hsu A, Williams D, Dashwood RH, Stevens J, Ho E (2011) Metabolism and tissue distribution of sulforaphane in Nrf2$^{-/-}$ and wild-type mice. *Pharm Res* 28: 3171-9. PMC3253624
147. Wang W, Jariyasopit N, Schrlau J, Jia Y, Tao S, Yu TW, Dashwood R, Zhang W, Wang X, Simonich SL (2011) Concentration and photochemistry of PAHs, NPAHs, and OPAHs and toxicity of PM2.5 during the Beijing Olympic Games. *Environ Sci Technol* 45: 6887-95. PMC3155004
148. Hsu A, Wong CP, Williams DE, Dashwood RH, Ho E (2011) Promoter de-methylation of *Cyclin D2* by sulforaphane in prostate cancer cells. *Clin Epigenetics* 2:3. PMC3257546
149. Ho E, Beaver LM, Williams DE, Dashwood RH (2011) Dietary factors and epigenetic regulation for prostate cancer prevention. *Adv Nutr 2:* 497-510. PMC3226387
150. Rajendran P, Ho E, Williams DE, Dashwood RH (2011) Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. *Clin Epigenetics* 3:4. PMC3255482. [Highly accessed]
151. Hasaniya NW, Premaratne S, Zhang WW, Razzuk A, Abdul-Ghani AA, Dashwood RH, Eklof B, Tinsley L, McNamara JJ (2011) Amelioration of ischemia-reperfusion injury in an isolated rabbit lung model using OXANOH. *Vasc Endovascular Surg* 45: 581-91.
152. McQuistan TJ, Simonich MT, Pratt MM, Pereira CB, Hendricks JD, Dashwood RH, Williams DE, Bailey GS (2012) Cancer chemoprevention by dietary chlorophylls: a 12,000-animal dose-response matrix biomarker and tumor study. *Food Chem Toxicol* 50: 341-52.
153. Shorey LE, Hagman AM, Williams DE, Ho E, Dashwood RH, Benninghoff AD (2012) 3,3'-diindolylmethane induces G_1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia cells. *PLoS One* 7: e34975. PMC3325915.
154. Lee S-H, Richardson RL, Dashwood RH, Baek SJ (2012) Capsaicin represses transcriptional activity of β-catenin in human colorectal cancer cells. *J Nutr Biochem* 23:646-55. PMC3197951
155. Parasramka M, Ho E, Williams DE, Dashwood RH (2012) MicroRNAs, diet, and cancer: new mechanistic insights on epigenetic actions of phytochemicals. *Mol Carcinog* 51: 213-30. PMC3196802

156. Parasramka MA, Dashwood WM, Wang R, Abdelli A, Bailey GS, Williams DE, Ho E, Dashwood RH (2012) MicroRNA profiling of carcinogen-induced rat colon tumors and the influence of dietary spinach. *Mol Nutr Food Res* 56:1259-69. PMC3762592
157. Beaver LM, Yu TW, Sokolowski EI, Williams DE, Dashwood RH, Ho E (2012) 3,3'-diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. *Toxicol Appl Pharmacol* 263(3):345-51. PMC3428467
158. Romagnolo DF, Dashwood R, Stover PJ, Waterland RA, Ziegler TR (2012) Nutritional regulation of epigenetic changes. *Adv Nutr* 3(5):749-50. PMC3648767
159. Parasramka M, Dashwood WM, Wang R, Saeed HH, Williams DE, Ho E, Dashwood RH (2012) A role for low-abundance miRNAs in colon cancer: the miR-206/Krüppel-like factor 4 (KLF4) axis. *Clin Epigenetics* 4:16. PMC3506528
160. Wang R, Löhr CL, Fischer K, Dashwood WM, Greenwood JA, Ho E, Williams DE, Ashktorab H, Dashwood MR, Dashwood RH (2013) Epigenetic inactivation of endothelin-2 (ET-2) and ET-3 in colon cancer. *Int J Cancer* 132:1004-12. PMC3500448.
161. Cerella C, Michiels C, Dashwood RH, Surh YJ, Diederich M (2013) Metabolism and cancer: old and new players. *Int J Cell Biol* 293201. PMC3706066
162. Shorey LE, Madeen EP, Atwell LL, Ho E, Löhr CV, Pereira CB, Dashwood RH, Williams DE (2013) Differential modulation of dibenzo[*def,p*]chrysene transplacental carcinogenesis: maternal diets rich in indole-3-carbinol versus sulforaphane. *Toxicol Appl Pharmacol* 270(1):60-9. PMC3999518
163. Kaur P, Shorey LE, Ho E, Dashwood RH, Williams DE (2013) The epigenome as a potential mediator of cancer and disease prevention in prenatal development. *Nutr Rev* 71:441-57. PMC3703873
164. Rajendran P, Kidane AI, Yu TW, Dashwood WM, Bisson W, Löhr CV, Ho E, Williams DE, Dashwood RH (2013) HDAC turnover, CtIP acetylation, and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates. *Epigenetics* 8(6):612-23. PMC3857341.
165. Watson, G., Beaver, L., Williams, D., Dashwood, R. and Ho, E. (2013) Phytochemicals from cruciferous vegetables, epigenetics, and prostate cancer prevention. *AAPS J* 15:951-961. PMC3787240.
166. Jariyasopit N, McIntosh M, Zimmermann K, Arey J, Atkinson R, Cheong PH, Carter RG, Yu TW, Dashwood RH, Massey Simonich SL (2014) Novel nitro-PAH formation from heterogeneous reactions of PAHs with NO_2, NO_3/NO_2O_5, and OH radicals: prediction, laboratory studies, and mutagenicity. *Environ Sci Technol* 48:412-9. PMC4125200
167. Jariyasopit N, Zimmermann K, Schrlau J, Arey J, Atkinson R, Yu T-W, Dashwood RH, Tao S, Massey Simonich SL (2014) Heterogeneous reactions of particulate matter-bound PAHs and NPAHS with NO_3/NO_2O_5, OH radicals, and O_3 under simulated long-range atmospheric transport conditions: reactivity and mutagenicity. *Environ Sci Technol* 48:10155-64. PMC4152393
168. Wong CP, Hsu A, Buchanan A, Palomera-Sanchez Z, Beaver LM, Houseman EA, Williams DE, Dashwood RH, Ho E (2014) Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. *PLoS One* 9:e86787 PMC3899342
169. Beaver LM, Buchanan A, Sokolowski EI, Riscoe AN, Wong CP, Chang JH, Löhr CV, Williams DE, Dashwood RH, Ho E (2014) Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention. *Mol Nutr Food Res* 58:2011-13. PMC4184971
170. Kang Y, Nian H, Rajendran P, Kim E, Dashwood WM, Pinto JT, Boardman LA, Thibodeau SN, Limburg PJ, Löhr CV, Bisson WH, Williams DE, Ho E, Dashwood RH (2014) HDAC8 and STAT3 repress *BMF* gene activity in colon cancer cells. *Cell Death Disease* 5:e1476. PMC4237248

171. Watson GW, Wickramasekara S, Palomera-Sanchez Z, Black C, Maier CS, Williams DE, Dashwood RH, Ho E (2014) SUV39H1/H3K9me3 attenuates sulforaphane-induced apoptosis signaling in PC3 prostate cancer cells. *Oncogenesis* 3:e131. PMC4275561
172. Atwell LL, Hsu A, Wong CP, Stevens JF, Bella D, Yu TW, Pereira CB, Löhr CV, Christensen JM, Dashwood RH, Williams DE, Shannon J, Ho E (2015) Absorption and chemopreventive targets of sulforaphane in humans following consumption of broccoli sprouts or a myrosinase-treated broccoli sprout extract. *Mol Nutr Food Res* 59:424-33. PMC4394840
173. Atwell LL, Beaver LM, Shannon J, Williams DE, Dashwood RH, Ho E (2015) Epigenetic regulation by sulforaphane: opportunities for breast and prostate cancer chemoprevention. *Curr Pharmacol Rep* 1:102-111. PMC4450146
174. Watson GW, Wickramasekara S, Maier CS, Williams DE, Dashwood RH, Ho E (2015) Assessment of global proteome in LNCaP cells by 2D-RP LC-MS/MS following sulforaphane exposure. *EuPA Open Proteomics* 9:34-40. PMC4666544
175. Nolte-'t Hoen EN, Van Rooij E, Bushell M, Zhang CY, Dashwood RH, James WP, Harris CC, Baltimore D (2015) The role of microRNA in nutritional control. *J Intern Med* 278:99-109.
176. Buchert M, Rohde F, Eissmann M, Tebbutt NC, Williams BB, Tan CW, Owen A, Hirokawa Y, Gnann A, Orend G, Orner G, Dashwood RH, Heath JK, Ernst M, Janssen KP (2015) A hypermorphic epithelial β-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations. *Dis Model Mech* 8:1361-73. PMC4631784
177. Watson GW, Wickramasekara S, Fang Y, Palomera-Sanchez Z, Maier CS, Williams DE, Dashwood RH, Perez VI, Ho E (2015) Analysis of autophagic flux in response to sulforaphane in metastatic prostate cancer cells. *Mol Nutr Food Res* 59:1954-61. PMC4651621
178. Rajendran P, Dashwood WM, Li L, Kang Y, Kim E, Johnson G, Fischer KA, Löhr CV, Williams DE, Ho E, Yamamoto M, Lieberman DA, Dashwood RH (2015) Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon. *Clin Epigenetics* 7:102. PMC4575421 [highly accessed]
179. Paquette CE, Kent ML, Peterson TS, Wang R, Dashwood RH, Löhr CV (2015) Immunohistochemical characterization of intestinal neoplasia in zebrafish *Danio rerio* indicates epithelial origin. *Dis Aquat Org* 116:191-197. PMC4695397
180. Kim E, Bisson WH, Löhr CV, Williams DE, Ho E, Dashwood RH, Rajendran P (2016) Histone and non-histone targets of dietary deacetylase inhibitors. *Curr Top Med Chem* 16:714-31. PMC5087604
181. Watson G, Wickramasekara S, Fang Y, Maier C, Williams DE, Dashwood RH, Perez VI, Ho E (2016) HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells. *Expl Biol Med (Maywood)* 241:1177-85. PMC4950308
182. Kim H, Banerjee N, Ivanov I, Prudhomme KR, Bisson WH, Dashwood RH, Talcott ST, Mertens-Talcott, SU (2016) Comparison of anti-inflammatory mechanisms of mango (*Mangifera indica L.*) and pomegranate (*Punica granatum L.*) in a preclinical model of colitis. *Mol Nutr Food Res* 60:1912-23. PMC502664 [Front Cover]
183. Ertem F, Rajendran P, Dashwood WM, Raju GS, Dashwood RH (2016) Development of a murine colonoscopic polypectomy model. *Gastrointest Endosc* 83:1272-6. PMC4875801
184. Wang R, Kang Y, Löhr CV, Fischer K, Bradford C, Johnson G, Dashwood WM, Williams DE, Ho E, Dashwood RH (2016) Reciprocal regulation of *BMF* and *BIRC5* (Survivin) linked to Eomes overexpression in colorectal cancer. *Cancer Lett* 381:341-8. PMC5035225
185. Kim H, Banerjee N, Pfent CM, Talcott ST, Dashwood RH, Mertens-Talcott SU (2017) Mango polyphenolics reduce inflammation in intestinal colitis – involvement of the miR-126/ PI3K/ AKT/ mTOR axis *in vitro* and *in vivo*. *Mol Carcinogen* 56:197-207. PMC5053910
186. Madeen E, Löhr CV, You H, Siddens E, Krueger S, Dashwood RH, Gonzalez F, Baird W, Ho E, Bramer L, Waters K, Williams DE (2017) Dibenzo[*def,p*]chrysene transplacental carcinogenesis in wild-type, *Cyp1b1* knockout and *CYP1B1* humanized mice. *Mol Carcinogen* 56:163-171. PMC26990437

187. Kumar R, Herold JL, Schady D, Davis J, Kopetz S, Martinez-Moczygemba M, Murray BE, Han F, Li Y, Callaway E, Chapkin RS, Dashwood WM, Dashwood RH, Berry T, Mackenzie C, Xu Y (2017) *Streptococcus gallolyticus subsp. gallolyticus* promotes colorectal tumor development. *PLoS Pathog* 13:e1006440. PMC5509344
188. Ertem FU, Zhang W, Chang K, Dashwood WM, Rajendran P, Sun D, Abudayyeh A, Vilar E, Abdelrahim M, Dashwood RH (2017) Oncogenic targets *Mmp7*, *S100a9*, *Nppb* and *Aldh1a3* from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam. *Int J Cancer* 140:460-468.
189. Johnson GS, Li J, Beaver LM, Dashwood WM, Sun D, Rajendran P, Williams DE, Ho E, Dashwood RH (2017) A functional pseudogene, *NMRAL2P*, is regulated by Nrf2 and serves as a co-activator of *NQO1* in sulforaphane-treated colon cancer cells. *Mol Nutr Food Res* 61:10.1002/mnfr.201600769. PMC5380536 [Front Cover]
190. Beaver LM, Kuintzle R, Buchanan A, Wiley MW, Glasser ST, Wong CP, Johnson GS, Chang JH, Löhr CV, Williams DE, Dashwood RH, Hendrix DA, Ho E (2017) Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer. *J Nutr Biochem* 42:72-83. PMC5360475
191. Palomera-Sanchez Z, Watson GW, Wong CP, Beaver LM, Williams DE, Dashwood RH, Ho E (2017) The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells. *J Nutr Biochem* 47:113-119. PMC5583029
192. Wang R, Chen Y-S, Dashwood WM, Li Q, Löhr CV, Fischer KA, Ho E, Williams DE, Dashwood RH (2017) Divergent roles of p120-catenin isoforms linked to altered cell viability, proliferation, and invasiveness in carcinogen-induced rat skin tumors. *Mol Carcinogen* 56:1733-1742. PMC5479755
193. Chen Y-S, Wang R, Dashwood WM, Löhr CV, Williams DE, Ho E, Mertens-Talcott S, Dashwood RH (2017) A miRNA signature for an environmental heterocyclic amine defined by a multi-organ carcinogenicity bioassay in the rat. *Arch Toxicol* 91:3415-25. PMC5836314
194. Yun C, Dashwood WM, Shatzer K, Kwong LN, Gao S, Yin T, Ling Q, Singh R, Dashwood R, Hu M (2018) Accurate quantification of PGE2 in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC-MS/MS. *J Pharm Biomed Anal* 148:42-50. PMC5698167
195. Hasaniya NW, Premaratne S, Zhang WW, Razzuk AM, McNamara JJ, Dashwood RH (2018) Preparation, characterization, and electron paramagnetic resonance (EPR) spectroscopic studies of OXANOH. *Free Radical Antioxidants* 8:578-582.
196. Beaver LM, Watson G, Clarke J, Glassner S, Wong C, Zhang Z, Williams DE, Dashwood RH, Löhr CV, Shannon J, Ho E (2017) Broccoli sprouts delay prostate cancer formation and decrease prostate cancer severity with a concurrent decrease in HDAC3 protein expression in TRAMP mice. *Curr Develop Nutr* 2:nzy002. PMC6041877
197. Housely L, Magana AA, Hsu A, Beaver LM, Wong CP, Stevens JF, Choi J, Jiang Y, Bella D, Williams DE, Maier CS, Shannon J, Dashwood RH, Ho E (2018) Untargeted metabolomic screen reveals changes in human plasma metabolite profiles following consumption of fresh broccoli sprouts. *Mol Nutr Food Res* 62:e1700665. PMC6310001
198. Reddy DS, Wu X, Golub VM, Dashwood WM, Dashwood RH (2018) Measuring histone deacetylase inhibition in mouse brain. *Curr Protocol Pharmacol* 81:e41. PMC6019607
199. Okonkwo A, Mitra J, Johnson GS, Li L, Dashwood WM, Hedge M, Chen Y, Dashwood RH, Rajendran P (2018) Heterocyclic analogs of sulforaphane trigger DNA damage and impede HR/NHEJ pathways in colon cancer cells: interplay of HATs and HDACs. *Mol Nutr Food Res* 62:e1800228. PMC6553464
200. Zhong X, Winston JH, Luo X, Kline KT, Nayeem SZ, Cong Y, Savidge TC, Dashwood RH, Powell DW, Li Q (2018) Neonatal colonic inflammation epigenetically aggravates epithelial IL-1β responses to injury in adult life. *Cell Mol Gastroenterol Hepatol* 6:65-78. PMC6008258
201. Zhang J, Tan P, Guo L, Gong J, Ma J, Li J, Lee M, Fang S, Jing J, Johnson S, Sun D, Cao WM, Dashwood R, Han L, Zhou Y, Dong WG, Huang Y (2019) p53-dependent autophagic

degradation of TET2 modulates cancer therapeutic resistance. *Oncogene* 38:1905-19. PMC6419514
202. Rajendran P, Johnson GS, Li L, Chen YS, Dashwood WM, Nguyen N, Ulusan AM, Ertem FU, Zhang M, Li J, Sun D, Huang Y, Wang S, Cheung HCE, Lieberman DA, Beaver LM, Ho E, Bedford MT, Chang K, Vilar E, Dashwood RH (2019) Acetylation of CCAR2 establishes a BET/BRD9 acetyl switch in response to combined deacetylase and bromodomain inhibition. *Cancer Res* 79:918-927. PMC6397680
203. Zhang Z, Garzotto M, Davis II EW, Mori M, Stoller WA, Farris PE, Wong CP, Beaver LM, Thomas GV, Williams DE, Dashwood RH, Hendrix DA, Ho E, Shannon J (2020) Sulforaphane bioavailability and chemopreventive activity in men presenting for biopsy of the prostate gland: a randomized controlled trial. *Nutr Cancer* 72: 74-87. PMC8244813
204. Kline KT, Lian H, Zhong XS, Luo X, Winston JH, Cong Y, Savidge TC, Dashwood RH, Powell DW, Li Q (2020) Neonatal injury increases gut permeability by epigenetically suppressing E-cadherin in adulthood. *J Immunol* 204:980-9. PMC7002285
205. Bhattacharjee S, Li J, Dashwood RH (2020) Emerging crosstalk between long non-coding RNAs and Nrf2 signaling. *Cancer Lett* 490: 154-64. PMID: 32717274
206. Johnson GS, Rajendran P, Dashwood RH (2020) CCAR1 and CCA2 as gene chameleons with antagonistic duality: preclinical, human translational and mechanistic basis. *Cancer Sci* 111:3416-25. PMC7540973
207. Bhattacharjee S, Dashwood RH (2020) Epigenetic regulation of NRF2/KEAP1 by phyto-chemicals. *Antioxidants* (Basel) 9:865. PMC7555619
208. Davis JS, Kanikarla P, Gagea M, Yu PL, Fang D, Sebastian M, Yang P, Hawk E, Dashwood R, Lichtenberger LM, Menter D, Kopetz S (2020) Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. *BMC Cancer* 20:871. PMC7488444
209. Li J, Zhao S, Lee M, Yin Y, Zhou Y, Ballester LY, Esquenazi Y, Dashwood RH, Davies PJA, Parson DW, Li X-N, Huang Y, Sun D (2020) Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma. *Science Adv* 6:eabb5425. PMC7567591
210. Dashwood RH (2020) Memories of a friend and colleague – Takashi Sugimura. *Mutat Res* 786:108337. [Front Cover]
211. Damiani E, Duran MN, Mohan N, Rajendran P, Dashwood RH (2020) Targeting epigenetic 'readers' with natural compounds for cancer interception. *J Cancer Prev* 25:189-203 [Front Cover]. PMC7783241
212. Ulusan AM, Rajendran P, Dashwood WM, Yavuz OF, Kapoor S, Gustafson T, Savage MI, Brown PH, Sei S, Mohammed A, Vilar E, Dashwood RH (2021) Optimization of erlotinib plus sulindac dosing regimens for intestinal cancer prevention in an Apc-mutant model of Familial Adenomatous Polyposis. *Cancer Prev Res* 14:325-336. PMC8137519
213. Dashwood RH (2021) Cancer interception by interceptor molecules: mechanistic, preclinical and human translational studies with chlorophylls. *Genes Environ* 43: 8 PMC7937315
214. Kapoor S, Gustafson T, Zhang M, Chen YS, Li J, Nguyen N, Tovar Perez JE, Dashwood WM, Rajendran P, Dashwood RH (2021) Deacetylase plus bromodomain inhibition downregulates *ERRC2* and suppresses the growth of metastatic colon cancer cells. *Cancers* 13: 1438. PMC8004213
215. Miller MS, Allen PJ, Brown PH, Chan A, Clapper ML, Dashwood RH, Demehri S, Disis ML, DuBois RN, Glynn RJ, Kensler TW, Khan SA, Johnson BD, Liby KT, Lipkin SM, Mallery SR, Meuillet EJ, Roden R, Schoen RE, Sharp ZD, Shirwan H, Siegfried JM, Rao CV, You M, Vilar E, Szabo E, Mohammed A (2021) Translational advances in cancer prevention agent development. *J Cancer Prev* 26: 71-82. PMC8020174
216. Chen YS, Li J, Huang Y, Dashwood WM, Zhang K, Sun D, Dashwood RH (2021) Dietary spinach reshapes the gut microbiome in an Apc-mutant genetic background: mechanistic insights from integrated multi-omics. *Gut Microbes* 13: 1972756. PMC8437542

217. Mohammad A, Dashwood RH, Dickinson S, Disis ML, Jaffee EM, Johnson BD, Khleif SN, Pollak MN, Schlom J, Shoemaker RH, Stanton SE, Wondrak GT, You M, Zhu H, Miller MS (2021) Translational advances in cancer prevention agent development (TACPAD) on immunomodulatory agents. *J Cancer Prev* 26: 309-317. PMC8749317
218. Chen Y-S, Li J, Neja S, Kapoor S, Tovar Perez JE, Tripathi C, Menon R, Jayaraman A, Lee K, Dashwood WM, Wang S, Zhang K, Kobayashi K, Rajendran P, Dashwood RH (2022) Metabolomics of acute *vs*. chronic spinach intake in an Apc-mutant genetic background: linoleate and butanoate metabolites targeting HDAC activity and IFN-γ signaling. *Cells* 11: 573. PMC8834217
219. Xiao Y, Lian H, Zhong XS, Krishnachaitanya SS, Cong Y, Dashwood RH, Savidge TC, Powell DW, Liu X, Li Q (2022) Matrix metalloproteinase 7 contributes to intestinal barrier dysfunction by degrading tight junction protein Claudin-7. *Front Immunol* 13:1020902. PMC9581388
220. Kapoor S, Damiani E, Wang S, Dharmanand R, Tripathi C, Tovar Perez JE, Dashwood WM, Rajendran P, Dashwood RH (2022) BRD9 inhibition by natural polyphenols targets DNA damage/repair and apoptosis in human colon cancer cells. *Nutrients* 14:4317. PMC9610492
221. Zhang S, Kapoor S, Tripathi C, Tovar Perez J, Mohan N, Dashwood WM, Zhang K, Rajendran P, Dashwood R (2023) Targeting ACE2-BRD4 crosstalk in colorectal cancer and the deregulation of DNA repair and apoptosis. *npj Precision Oncol* 7:20.
222. An N et al., (2023) Combinatorial epigenetic therapeutics synergistically enhance MHC-I-dependent anticancer immunity through NLRC5. *J Immunother Cancer*, under revision.
223. Tripathi C, Tovar Perez JE, Kapoor S, Muhsin A, Dashwood WM, Demirhan Y, Demirhan M, Shapiro A, Mohammed A, Sei S, Brown PH, Savage MI, Vilar E, Rajendran P, Dashwood RH (2023) Immunomodulatory activity of intermittent low-dose erlotinib plus sulindac: implications for hereditary and sporadic colorectal cancer. *Cancer Immunol Res*, submitted.

BOOK CHAPTERS

1. Dashwood RH, Combes RD (1988) Mutagenic activity of four compounds (2AAF/4AAF and benzo[a]pyrene/pyrene) and their respective rat urine concentrates using *Salmonella typhimurium* strain TA98. In: "*Evaluation of Short-Term Tests for Carcinogens – Report of the International Programme on Chemical Safety's (IPCS) Collaborative Study on In Vivo Assays*". Cambridge University Press, Vol II, pp.2.113-2.118.
2. Williams DE, Dashwood RH, Hendricks JD, Bailey GS (1989) Anticarcinogens and tumor promoters in foods. In: "*Food Toxicology, A Perspective on the Relative Risks*". IFT Basic Symposium Series (eds. SL Taylor, RA Scanlan). Marcel Dekker, New York, Basel, Chapter 5, pp.101-150.
3. Dashwood RH, Fong AT, Hendricks JD, Bailey GS (1990) Tumor dose- response studies with AFB1 and the ambivalent modulator indole-3-carbinol: inhibitory vs. promotional potency. In: "*Antimutagenesis and Anticarcinogenesis Mechanisms II*" (eds. Y Kuroda, DM Shankel, and MD Waters). Plenum, New York, pp.361-365.
4. Dashwood RH, Loveland PM, Fong AT, Hendricks JD, Bailey GS (1990) Combined in vivo DNA binding and tumor dose-response studies to investigate the molecular dosimetry concept. In: "*Mutation and the Environment – Part D: Carcinogenesis*". (eds. M Mendelsohn, RJ Albertini). Wiley-Liss, New York, pp.335-344.
5. Bailey GS, Dashwood RH, Fong AT, Scanlan R, Hendricks JD (1991) Modulation of mycotoxin and nitrosamine carcinogenesis by I3C: quantitative analysis of inhibition versus promotion. In: "*Relevance to Human Cancer of N-nitroso Compounds, Tobacco Smoke, and Mycotoxins*". (eds. IK O'Neill, J Chen, H Bartsch). IARC, Lyon, France, pp. 275-280.
6. Dashwood RH, Marien K, Loveland P, Williams DE, Hendricks JD, Bailey GS (1992) Formation of aflatoxin-DNA adducts in trout and their use as molecular dosimeters for tumor prediction. In "*Handbook of Applied Mycology*" (eds. D Bhatnagar, E Lillehoj, DK Aurora). Marcel Dekker Inc., New York, Vol V: Mycotoxins pp.183-211.

7. Dashwood RH, Guo D (1994) Protective properties of chlorophylls against the covalent binding of heterocyclic amines to DNA in vitro and in vivo. In: "*Heterocyclic Amines in Cooked Foods: Possible Human Carcinogens*", Proceedings of the 23rd International Symposium of the Princess Takamatsu Cancer Research Fund, (eds. RH Adamson et al.). Princeton Scientific Publishing Co., New Jersey, pp.181-189.
8. Dashwood RH (1997) Inhibition of tumorigenesis by chlorophyllin. In: "*Fundamentals of Cancer Prevention*" Proceedings of the 27th International Symposium of the Princess Takamatsu Cancer Research Fund, (eds. AH Conney et al.). Princeton Scientific Publishing Co., New Jersey, pp.181-189. pp. 30-33.
9. Dashwood RH (2000) Modulation of the Mutagenicity and Carcinogenicity of Heterocyclic Amines. In: "*Food Borne Carcinogens: Heterocyclic Amines*" (eds. M Nagao and T Sugimura). J. Wiley & Sons, Ltd., Sussex, England, Chapter 9, pp. 285-312.
10. Dashwood RH, Ho E (2008) The emerging epigenetic model of colon cancer, and the role of dietary histone deacetylase (HDAC) inhibitors. In: "*Current Challenges in the Understanding and Management of Colon Cancer*" Proceedings of the 38th International Symposium of the Princess Takamatsu Cancer Research Fund, (eds. W Dove et al.). Princeton Scientific Publishing Co., New Jersey, Vol. pp. 94-98.
11. Delage B, Dashwood RH (2009) Nutrients, histone modifications, and chromatin remodeling in chronic inflammation. In: "*Nutrients and Epigenetics*" (eds. SW Choi, S Friso). CRC Press (Taylor & Francis), Chapter 6, pp. 127-54.
12. Delage B, Dashwood RH (2009) Targeting the epigenome with dietary agents. In: "*Dietary Modulation of Cell Signaling Pathways*" (eds. L Packer, Z Dong, E Cadenas and JY Surh). CRC Press (Taylor & Francis), Chapter 13, pp. 337-69.
13. Beaver L.M., Williams D.E., Dashwood R.H., Ho E. (2012) Chemoprevention of prostate cancer with cruciferous vegetables: role of epigenetics. (eds. S Shankar and RK Srivastava). *Nutrition, Diet, and Cancer*, Philadelphia: Springer. Chapter 3, pp. 49-81.

ABSTRACTS

1. Dashwood RH, Combes RD, Ashby J (1986) Adaptation of in vitro and in vivo DNA binding assays to discriminate between a carcinogen/non-carcinogen pair of monoazo dyes. *Mutagenesis* 1:389.
2. Dashwood RH, Combes RD (1986) Mutagenicity of the two carcinogen/non-carcinogen pairs benzo[*a*]pyrene/pyrene and 2-acetylaminofluorene/4-acetylaminofluorene and their respective rat urine concentrates as part of the IPCS International Trial. *Mutagenesis* 1:76.
3. Dashwood RH (1987) The relationship between covalent DNA binding and revertant yield in the Salmonella mutagenicity assay: implications for assay specificity. *Environ Mutagenesis* 9:27.
4. Dashwood RH, Combes RD, Ashby J (1987) On the lack of specificity of the Salmonella mutagenicity assay. *Mutagenesis* 2:301.
5. Dashwood RH, Arbogast D, Fong A, Hendricks JD, Bailey G (1988) In vivo DNA binding dose-response studies with AFB1 and the anticarcinogen indole-3-carbinol. *Toxicologist* 8:169.
6. Dashwood RH, Arbogast D, Fong A, Hendricks J, Bailey GS (1988) Concomitant in vivo DNA binding/tumor dose-response studies with AFB1 and the natural inhibitor indole-3-carbinol. *Proc AACR* 29:135.
7. Dashwood RH, Hendricks J, Fong A, Bailey GS (1989) Inhibitory vs promotional potency, and timing of modulator treatment: tumor dose-response studies with aflatoxin B1 and indole-3-carbinol. *Proc AACR* 30:180.
8. Dashwood RH, Hendricks JD, Bailey GS (1990) Mechanisms of antimutagenesis/ anticarcinogenesis by the natural tumor modulator indole-3-carbinol. *Environ Mol Mutagen* 15:15.

9. Bailey GS, Fong A, Dashwood RH, Hendricks JD, Williams DE (1990) Mechanisms of anticarcinogenesis by the natural tumor modulator indole-3-carbinol. *Proc AACR* 31:122.
10. Takahashi N, Stresser D, Williams D, Dashwood R, Bailey GS (1991) Indole-3-carbinol induction of cytochrome P4501A1 is not relevant to its modulation of carcinogenesis. *Proc AACR* 32:124.
11. Bailey GS, Breinholt V, Dashwood RH (1991) Chemopreventive properties of dietary chlorophyllin: dose-responsive inhibition of aflatoxin and heterocyclic amine genotoxicity in vivo and in vitro. *Proc AACR* 32:135.
12. Dashwood RH (1991) Chlorophyllin inhibition of carcinogen-DNA binding in vivo and direct antimutagenic activity versus AFB1-8,9-epoxide. *Environ Mol Mutagen* 17:19.
13. Dashwood RH, Guo D (1992) Inhibition of IQ-DNA binding by chlorophyllin: studies of enzyme inhibition and molecular complex formation. *Proc AACR* 33:162.
14. Guo D, Dashwood RH (1993) Dose-related inhibition of 2-amino-3-methylimidazo[4,5-*f*]quinoline (IQ)-DNA binding in rats given chlorophyllin. *Proc AACR* 34:124.
15. Yamane S, Guo D, Larsen R, Dashwood RH (1994) Computer-generated models of carcinogen-inhibitor complexes. *Proc AACR* 35:144.
16. Dashwood RH, Larsen R (1994) Spectroscopic and molecular modeling studies of caffeine complexes with DNA intercalating drugs. *Bull Genetic Soc Can* 25:27.
17. Guo D, Horio D, Dashwood RH (1994) Inhibition and enhancement of carcinogenesis in rats given chlorophyllin and 2-amino-3-methylimidazo[4,5-*f*]quinoline. *Bull Genetic Soc Can* 25:28.
18. Guo D, Schut H, Snyderwine E, Dashwood RH (1994) Inhibition of DNA adducts and colon aberrant crypt foci in rats given 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP) and indole-3-carbinol. *Bull Genetic Soc Can* 25:28.
19. Guo D, Horio D, Dashwood RH (1995) Inhibition of carcinogenesis in F344 rats given chlorophyllin and 2-amino-3-methylimidazo[4,5-*f*]quinoline. *Proc AACR* 36:596.
20. Xu M, Dashwood RH (1996) The role of enzyme induction versus enzyme inhibition in the antimutagenic activity of indole-3-carbinol. *Environ Mol Mutagen* 27:77.
21. Hayashi R, Horio D, Dashwood RH (1996) Loss of apoptosis in colon tumors induced in the rat by 2-amino-3-methylimidazo[4,5-*f*]quinoline (IQ). *Proc AACR* 37:127.
22. Xu M, Bailey AC, Hernaez J, Taoka C, Dashwood RH (1996) Protection by green tea, black tea, and indole-3-carbinol against 2-amino-3-methylimidazo[4,5-*f*]quinoline (IQ)-induced colonic aberrant crypts in the F344 rat. *Proc AACR* 37:265.
23. Hernaez J, Dashwood RH (1997) Protection by green and black teas against 2-amino-3-methylimidazo[4,5-*f*]quinoline: a study of inhibitory mechanisms. *Proc AACR* 38:208.
24. Xu M, Dashwood RH (1998) Decreased sensitivity of the F344 rat to induction of colonic aberrant crypt foci by 2-amino-3-methylimidazo[4,5-*f*]quinoline after treatment with AIN-93G versus AIN-76A and chow diets. *Proc AACR* 39:395-396.
25. Xu M, Blum CA, Fong AT, Bailey GS, Stoner GD, Horio D, Dashwood RH (2000) β-catenin mutation in colon tumors promoted by dietary phytochemicals. *Environ Mol Mutagen* 35:67.
26. Santana G, Xu M, Izquierdo-Pulido M, Dashwood RH (2000) Chemopreventive properties of white tea. *Proc AACR* 41:532.
27. Xu M, Blum CA, Fong AT, Orner G, Bailey GS, Stoner GD, Horio DT, Dashwood RH (2000) Altered pattern of β-catenin mutation in colon tumors promoted by two dietary phytochemicals. *Proc AACR* 41:685.
28. Amantana A, Santana-Rios G, Butler JA, Whanger PD, Dashwood RH (2000) Antimutagenic activity of selenium-enriched green tea towards a cooked meat mutagen. *FASEB J* 14:A537.
29. Franke AA, Dashwood RH, Xu M, Custer LJ (2000) Cancer-protective effects and bioavailability of flavonoids. *Proc Am Chem Soc*, 219: 182-AGFD Part 1.
30. Santana-Rios G, Provost C, Amantana A, Dashwood RH (2000) Antimutagenic activity of white tea. *Proc Am Chem Soc*, 219: 85-TOXI Part 1.

31. Blum C, Xu M, Orner G, Michels A, Bailey G, Dashwood RH (2001) β–catenin mutations in multiple target organs following treatment of F344 rats with dietary phytochemicals and 1,2-dimethylhydrazine or 2-amino-3-methylimidazo[4,5-*f*]quinoline. *Environ Mol Mutagen* 37:22.
32. Orner GA, Blum CA, Dashwood WM, Dashwood RH (2001) Effect of white tea on intestinal tumor progression in the *Apc*^{min} mouse. *Environ Mol Mutagen* 37:59.
33. Dashwood RH (2001) Antimutagenic and anticarcinogenic effects of white tea. *Mutat Res* 483 (Suppl. 1):S29.
34. Orner GA, Tebbutt NC, Dashwood WM, Ernst M, Dashwood RH (2002) Sensitivity of a mutant β–catenin mouse model to the heterocyclic amine PhIP. *Proc AACR* 43:172.
35. Li Q, Dixon B, Al-Fageeh M, Blum C, Dashwood RH (2002) Sequencing of the rat β-catenin gene (*Ctnnb1*) and mutational analysis of liver tumors induced by 2-amino-3-methylimidazo[4,5-*f*]quinoline. *Toxicol Sci* 66:7.
36. Orner GA, Dashwood WM, Li Q, Al-Fageeh M, Tebbutt N, Heath JK, Dashwood RH (2002) Cellular effects of tea antioxidants in vitro and in mouse models of colon cancer. *Free Rad Biol Med* 33:S302.
37. Mastaloudis A, Yu D, Frei B, Dashwood R, Traber M (2002) Gender differences in DNA damage produced during an ultramarathon run as measured by the comet assay. *Free Rad Biol Med* 33:84.
38. Orner G, Dashwood WM, Tebbutt NC, Li Q, Heath JK, Myzak MC, Ernst M, Dashwood RH (2003) Cancer chemoprevention by a combination of white tea plus sulindac in a mouse model expressing an oncogenic form of β-catenin. *Cancer Epidemiol Biomarkers Prev* 12:1287S.
39. Myzak M, Dashwood RH (2003) Sulforaphane as a putative inhibitor of histone deacetylase. *Eur J Biochem* 270:155.
40. Myzak M, Dashwood RH (2004) Histone deacetylase inhibition by metabolites of sulforaphane. *Proc AACR* 45: Abstract 4036.
41. Yu D, Dashwood RH (2004) Antimutagenic activity of spearmint. *Environ Mol Mutagen* 44:239.
42. Orner G, Elias VD, Dashwood RH (2004) Modulation of Wnt signaling by tea plus celecoxib. *Cancer Epidemiol Biomarkers Prev* 13:1845S.
43. Myzak MC, Hardin K, Dashwood RH, Ho E (2004) HDAC inhibition by sulforaphane during hyperplasia, intermediate, and late stages of prostate cancer. *Cancer Epidemiol Biomarkers Prev* 13:1847S.
44. Hemingway RW, McGraw GW, Helms GL, Proteau RR, Mata JE, Dashwood RH (2004) Catechin-(4α,-8)-epigallocatechin-3-gallate: production, proof of structure, and properties. *Am Chem Soc* 228: U250.
45. Ashktorab H, Daremipouran M, Dashwood RH, Dashwood WM, Smoot DT (2005) *H. pylori*-induced apoptosis in human gastric cancer cells mediated via the release of AIF from mitochondria. *Proc AACR* 46: Abstract 2675.
46. Li Q, Zhong X, Dashwood WM, Nakagama H, Dashwood RH (2005) β-catenin upregulates Bcl-2 through a mechanism involving c-Myc and E2F1. *Proc AACR* 46: Abstract 1940.
47. Carter O, Wang R, Orner GA, Dashwood RH (2005) Blocking and suppressing effects of white tea, green tea, EGCG and caffeine in PhIP-treated rats, *Proc AACR* 46: Abstract 2477.
48. Orner GA, Elias VD, Carter O, Dashwood RH (2005) Chemoprevention by white tea in *Apc*^{min} mice. *Proc AACR* 46: Abstract 6065.
49. Myzak MC, Moussaoui MA, Dashwood RH (2005) In vivo inhibition of histone deacetylase by sulforaphane. *Proc AACR* 46: Abstract 2666.
50. Jubert C, Simonich M, Roebuck W, Orner G, Dashwood R, Williams D, Bailey G (2006) Chlorophylls purified by a new large-scale method inhibit aflatoxin carcinogenesis in the rat. *Proc AACR* 47: Abstract 3928.
51. Simonich M, McQuistan T, Jubert C, Pereira C, Hendricks J, Dashwood R, Williams D, Bailey G (2006) Natural chlorophyll inhibits dibenzo[*a,l*]pyrene-induced liver and stomach carcinogenesis in rainbow trout. *Proc AACR* 47: Abstract 3924.

52. Orner GA, Elias VD, Pereira C, Dashwood RH (2006) Interactions between white tea and sulindac in the prevention of intestinal cancer. *Proc AACR* 47: Abstract 4895.
53. Dashwood RH (2006) Weak ligands as HDAC inhibitors: useful for cancer prevention? *Chem-Biol Interact* 161: Abstract S24.
54. Myzak MC, Hardin K, Yan M, Tong P, Dashwood R, Ho E (2006) Sulforaphane inhibits HDAC activity in prostate cancer cells, retards growth of PC3 xenografts, and inhibits HDAC activity in vivo. *FASEB J* 20: A150 Part 1.
55. Li Q, Dashwood R (2006) Suppression of intestinal tumorigenesis by activator protein 2α. *Proc AACR* 47: Abstract 3016.
56. Bailey G, *et al.* (2007) Low dose aflatoxin B1 toxicokinetics and intervention in human volunteers: a pilot study. *Proc AACR* Abstract 1665.
57. Wang R, *et al.* (2007) Effects of white tea, EGCG and caffeine on PhIP-induced tumorigenesis and β-catenin expression. *Proc AACR* Abstract LB-144.
58. Kwon I, *et al.* (2008) Transcriptional silencing of β-catenin by PKG in colon cancer cells. *Proc AACR* Abstract 5288.
59. Bailey GS, *et al.* (2008) Effects of chlorophyll and chlorophyllin on AFB1 pharmacokinetics in human subjects. *Proc AACR* Abstract 500.
60. Dashwood RH (2010) Metabolism as a key to HDAC inhibition by dietary constituents. *FASEB J* 24: Abstract 413.1.
61. Surh YJ, Dashwood RH, Na HY, Ji LL (2011) Introduction to nutrition and physical activity in aging, obesity, and cancer. Ann NY Acad Sci 1229, vii-viii.
62. Beaver LM, Chang JH, Williams DE, *et al.* (2012) An RNA-seq approach to identify mechanisms by which the phytochemical sulforaphane acts to prevent prostate cancer. *FASEB J* 26:
63. Rajendran P, Kidane AI, Yu TW, Dashwood WM, Ho E, Williams DE, Dashwood RH (2012) Differential effects of sulforaphane and related isothiocyanates on HDAC turnover and the DNA damage response in colon cancer cells. *Proc AACR* Abstract LB-184.
64. Atwell L, Clarke JD, Hsu A, *et al*. (2013) Sulforaphane bioavailability and bioactivity in humans. *FASEB J* Abstract 636.26.
65. Bailey G, Mata J, Bench G, Tracewell W, Sudakin D, Pereira C, Garrard M, Dashwood R, Williams D, Jubert C, McQuistan T, Simonich M (2014) Low dose aflatoxin B1 toxicokinetics and intervention in human volunteers: a pilot study. *Cancer Res* 67 (9 Supplement) 1665.
66. Shorey LE, Kaur P, Rosato C, Houseman EA, Ho E, Dashwood RH, Benninghoff AD, Williams DE (2014) Analysis of genome-wide DNA methylation in CCRF-CEM cells confirms hypermethylation at reported epigenetic markers of T-cell lymphoblastic leukemia and identifies novel therapeutic targets with reduced methylation upon treatment with dietary indoles. *Cancer Res* 72 (8 Supplement) 5430.
67. Bailey G, Jubert C, Mata J, Dashwood R, Williams D, Tracewell W, Bench G, Turteltaub K (2014) Effects of chlorophyll and chlorophyllin on AFB1 pharmacokinetics in human subjects. *Cancer Res* 68 (9 Supplement) 500.
68. Kwon IK, Liu K, Dashwood R, Thangaraju M, Dulin N, Schoenlein P, Ganapathy V, Browning D (2014) *Cancer Res* 68 (9 Supplement) 5288.
69. Jubert C, Simonich M, Roebuck B, Orner G, Dashwood R, Williams D, Bailey G (2014) Chlorophylls purified by a new large-scale method inhibit carcinogenesis in the rat. *Cancer Res* 66 (8 Supplement) 924.
70. Orner GA, Elias VD, Pereira CB, Dashwood RH (2014) Interactions between white tea and sulindac in the prevention of intestinal cancer. *Cancer Res* 66 (8 Supplement) 1150.
71. Rajendran P, Kidane AI, Yu TW, Dashwood WM, Ho E, Williams DE, Dashwood RH (2014) Differential effects of sulforaphane and related isothiocyanates on HDAC turnover and the DNA damage response in colon cancer cells. *Cancer Res* 72 (8 Supplement) LB-184.
72. Wang R, Dashwood WM, Löhr C, Fischer K, Pereira C, Louderback M, Bailey G, Williams D, Dashwood R (2014) Effects of white tea, EGCG and caffeine on PhIP-induced tumorigenesis and β-catenin expression. *Cancer Res* 67 (9 Supplement) LB-144.

73. Beaver LM, Buchanan A, Sokolowski EI, *et al*. (2013) Genome-wide transcriptome analysis of the effects of sulforaphane on normal and prostate cancer cells. *FASEB J* Abstract 248.2.
74. Kaiser MC, Rajendran P, Dashwood WM, *et al*. (2013) An epigenetic perspective on pharmacologic ascorbate in colon cancer. *FASEB J* Abstract 248.3.
75. Li Q, Zhong X, Myzak MC, Dashwood WM, Dashwood RH (2014) APC acts as a transcription factor and downregulates the β-catenin gene, *CTNNB1*, and suppressor *SIAH1*. *Cancer Res* 64 (7 Supplement) 1170-71.
76. Ashktorab H, Daremipouran M, Dashwood R, Dashwood M, Smoot DT (2014) *H. pylori*-induced apoptosis in human gastric cancer cells mediated via the release of AIF from mitochondria. *Cancer Res* 65 (9 Supplement) 630.
77. Myzak M, Dashwood RH (2014) Histone deacetylase inhibition by metabolites of sulforaphane. *Cancer Res* 64 (7 Supplement) 9333.
78. Atwell L, Clarke J, Hsu A, Bella D, Stevens J, Dashwood R, Williams D, Ho E (2014) Bioavailability and metabolomic targets of sulforaphane in humans. *FASEB J* Abstract 1036.2.
79. Carter O, Wang R, Orner GA, Dashwood RH (2014) Blocking and suppressing effects of white tea, green tea, EGCG and caffeine in PhIP-treated rats. *Cancer Res* 65 (9 Supplement) 581.
80. Myzak MC, Moussaoui M, Dashwood RH (2014) In vivo inhibition of histone deacetylase by sulforaphane. *Cancer Res* 65 (9 Supplement) 628.
81. Li Q, Dashwood RH (2014) Suppression of intestinal tumorigenesis by activator protein 2α. *Cancer Res* 66 (8 Supplement) 710-10.
82. Li Q, Zhong X, Dashwood WM, Nakagama H, Dashwood RH (2014) β-Catenin upregulates Bcl-2 through a mechanism involving c-Myc and E2F1. *Cancer Res* 65 (9 Supplement) 454.
83. Johnson G, Beaver L, Williams DE, Ho E, Dashwood RH (2015) Regulation and function of Nrf2-associated long noncoding RNA. *Cancer Prev Res* 2015;8(10 Suppl): Abstract B33.
84. Ertem FU, Dashwood WM, Rajendran P, Raju GS, Rashid A, Dashwood R (2016) Novel polypectomy system in a preclinical model of colon cancer. *Cancer Res* 76 (14 Supplement) 839.
85. Chen YC, Wang R, Dashwood WM, Löhr CV, Williams DE, Ho E, Mertens-Talcott S, Dashwood RH (2017) A miRNA signature linked to human environmental risk defined from carcinogen-induced and genetically-driven colon carcinogenesis models. *Cancer Res* 77 (13 Supplement) 4428.
86. Ertem F, Zhang W, Chang K, Dashwood WM, Rajendran P, Sun D, Abudayyeh A, Abdulrahim M, Vilar E, Dashwood RH (2017) Prevention by tolfenamic acid and characterization of the molecular targets in Pirc and FAP colorectal adenomas. *Cancer Res* 77 (13 Supplement) 2229.
87. Zhong X, Luo X, Winston J, Nayeem S, Line K, Dashwood R, Savidge TC, Cong Y, Powell DW, Li Q (2018) Neonatal colonic inflammation aggravates epithelial injury through miR-196 when exposed to another episode on inflammation in adult-life. *DDW* 2018 Abstract #2912874.
88. Li Q, Zhong XS, Nyeem SZ, Line KT, Peng J, Fujise K, Dashwood R (2018) Experimental colitis impedes cardiac function through epigenetic mechanisms. *Eur Heart J* 39(suppl 1). DOI: 10.1093/eurheartj/ehy563.P4758
89. Lian H, Zhong XS, Kline K, Luo X, Winston JH, Cong Y, Dashwood R, Savidge TC, Powel DW, Li Q (2019) Matrix metalloproteinase 7 contributes to intestinal barrier dysfunction by suppressing tight junctions. *Gastroenterol* 156(6):S-211.
90. Ulusan A, Rajendran, Dashwood WM, Mohammed A, Sei S, Brown PH, Vilar E, Dashwood R (2019) Optimizing erlotinib plus sulindac dosing regimens in a preclinical model of FAP. *Cancer Res* DOI: 10.1158/1538-7445.SABCS18-5074
91. Johnson G, Rajendran P, Li L, Chen YS, Dashwood WM, Nguyen N, Ulusan AM, Ertem F, Zhang M, Sun D, Huang Y, Wang S, Leung H-C E, Lieberman D, Beaver LM, Ho E, Bedford MT, Chang K, Vilar E, Dashwood R (2019) CCAR2 acetylation establishes a BET/BRD9

acetyl switch in response to combined deacetylase and bromodomain inhibition. *Cancer Res* DOI: 10.1158/1538-7445.AM2019-2614
92. Davis JS, Marie PK, Yu PL, Gagea M, Fang D, Sebastian M, Yang P, Hawk E, Dashwood R, Lichtenberger LM, Menter D, Kopetz S (2020) Sulindac plus phospholipid is effective for polyp reduction and safer than sulindac alone. *Cancer Res* DOI: 10.1158/1538-7445.AM2020-1
93. Rajendran P, Ulusan A, Dashwood WM, Kapoor S, Mohammed A, Sei S, Rashid A, Brown PH, Vilar-Sanchez E, Dashwood RH (2020) Optimization of dosing regimens of sulindac in combination with erlotinib for small intestine and colorectal cancer prevention. *Cancer Res* DOI: 10.1158/1538-7445.AM2020-21
94. Rajendran P, Damiani E, Wang S, Dashwood W, Dashwood RH (2020) Dietary polyphenols as epigenetic 'reader' inhibitors. *Cancer Res* DOI: 10.1158/1538-7445.AM2020-3477
95. Zhong XS, Ou R, Liu M, Krishnachaitanya, Dashwood RH, Powell DW, Li Q (2023) Erlotinib suppresses tumorigenesis in a mouse model of colitis-associated cancer. DDW2023 DDW ePoster Library Li Q. 05/07/2023; 379818; Su1677.

MEETINGS/CONFERENCES

1. First International Conference on Immunotoxicology, Surrey, UK, 1983.
2. UK Environmental Mutagen Society, Liverpool University, UK, 1984.
3. UK Environmental Mutagen Society, Portsmouth, UK, 1985.
4. Fourth International Conference on Environmental Mutagens, Stockholm, Sweden, 1985.
5. British Society of Toxicology, Reading University, UK, 1986.
6. UK Environmental Mutagen Society, Manchester University, UK, 1986.
7. European Society of Toxicology, Harrogate, Yorkshire, UK, 1986.
8. Environmental Mutagen Society, San Francisco, CA, 1987.
9. Pacific Northwest Association of Toxicologists, Seattle, WA, 1987.
10. Society of Toxicology, 27th Annual Meeting, Dallas, TX, 1988.
11. American Association for Cancer Research, New Orleans, LA, 1988.
12. 2nd International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis, Ohito, Japan, 1988.
13. American Association for Cancer Research, San Francisco, CA, 1989.
14. 5th International Conference on Environmental Mutagens, Cleveland, OH, 1989. [**Invited Speaker**]
15. Environmental Mutagen Society, Albuquerque, NM, 1990.
16. American Association for Cancer Research, Washington DC, 1990.
17. Environmental Mutagen Society, Orlando, FL, 1991.
18. AICR International Conference on Research in Human Cancer, Atlanta, GA, 1991.
19. American Association for Cancer Research, San Diego, CA, 1992.
20. 23rd International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, Japan, 1992. [**Invited Speaker**]
21. 6th International Conference on Environmental Mutagens, Melbourne, Australia, 1993.
22. American Association for Cancer Research, Orlando, FL, 1993.
23. USDA W-122 Regional Meeting, Napa, CA, 1993.
24. 5th Heidelberger Conference, Honolulu, HI, 1994. [**Invited Speaker**]
25. American Association for Cancer Research, San Francisco, CA, 1994.
26. 4th International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis, Banff, Canada, 1994. [**Session Chair**]
27. USDA W-122 Regional meeting, Snowbird, UT, 1994.
28. AACR/JCA Meeting on Heterocyclic Amines and Human Cancer, Maui, HI, 1995. [**Invited Speaker**]
29. USDA W-122 Regional meeting, Honolulu, HI, 1995. [**Conference Organizer, Speaker**]
30. American Association for Cancer Research, Washington, D.C., 1996.

31. USDA W-122 Regional Meeting, Lake Tahoe, CA, 1996.
32. 27th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, Japan, 1996. [**Invited Speaker, Session Chair**]
33. 5th International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis, Okayama, Japan, 1996.
34. American Association for Cancer Research, San Diego, CA, 1997.
35. Japanese Cancer Association Annual meeting, Kyoto, Japan, 1997.
36. 28th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, Japan, 1997. [**Discussant**]
37. AACR/JCA Joint Conference on Prevention, Diagnosis, and Therapy of Cancer, Maui, HI, 1998.
38. American Association for Cancer Research, New Orleans, LA, 1998.
39. Basic and Clinical Research in Gastric Cancer, 11th International Symposium, Tokyo, Japan, 1998.
40. 2nd International Scientific Symposium on Tea and Health, Washington, DC, 1998. [**Invited Speaker**]
41. 29th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, Japan, 1998. [**Discussant**]
42. 7th International Conference on *N*-substituted Aryl Compounds, Nagoya, Japan, 1998. [**Invited Speaker**]
43. 9th Annual AICR Conference, Washington, DC, 1999. [**Invited Speaker**]
44. 8th Asian Congress of Nutrition, Seoul, South Korea, 1999. [**Invited Speaker**]
45. American Chemical Society, San Francisco, CA, 2000.
46. American Association for Cancer Research, San Francisco, CA, 2000.
47. Environmental Mutagen Society, New Orleans, LA, 2000. [**Invited Speaker**]
48. 20th International Symposium on “Gene Environment Interactions and Cancer Prevention”, Sapporo, Japan, 2000.
49. Phytochemicals and Inhibition of Cancer, Potsdam, Germany, 2000. [**Invited Speaker**]
50. Environmental Mutagen Society, San Diego, CA, 2001. [**Invited Speaker/Symposium Organizer**]
51. LPI Centennial Conference, Portland, OR, 2001. [**Invited Speaker, Organizing Committee**]
52. International Symposium on Dietary Antimutagens and Anticarcinogens, Seoul, South Korea, 2001. [**Invited Speaker**]
53. 8th International Conference on Environmental Mutagens, Shizuoka, Japan, 2001. [**Invited Speaker, Session Chair, Symposium co-organizer**]
54. 8th International Conference on *N*-Aryl Compounds, Washington, DC, 2001. [**Invited Speaker, Organizing Committee**]
55. Green Tea and Cancer: A Critical Review, Cold Spring Harbor Laboratory, NY, 2002. [**Invited Speaker**]
56. 14th International Symposium on Microsomes and Drug Oxidations, Sapporo, Japan, 2002.
57. European Research on Functional Effects of Antioxidants, Cambridge, UK, 2002. [**Invited Speaker**]
58. 9th Annual Meeting, Society of Free Radical Biology and Medicine, San Antonio, TX, 2002. [**Invited Speaker**]
59. Impact of the Environment on Colon Cancer, Miami, FL, 2003. [**Invited Speaker, Session Chair**]
60. LPI Diet and Optimum Health Conference, Portland, OR, 2003. [**Invited Chair, Organizing Committee Member**]
61. Free Radicals: Pros and Cons of Antioxidants, NIH, Bethesda, MD, 2003. [**Invited Speaker**]
62. Special FEBS Meeting on Signal Transduction, Brussels, Belgium, 2003.
63. 8th International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis, Pisa, Italy, 2003. [**Invited Speaker**]
64. 95th Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2004.

65. International Research Conference on Food, Nutrition and Cancer, Washington, DC, 2004. [**Invited Speaker**]
66. Niigata International Conference on Functional Foods for Prevention and Treatment of Disease, Niigata, Japan, 2004. [**Invited Speaker**]
67. AACR Frontiers in Cancer Prevention Conference, Seattle, WA, 2004. [**Invited Speaker**]
68. Current Prospects of Functional and Medicinal Foods, Jeju Island, South Korea, 2004. [**Invited Speaker**]
69. 96th Annual Meeting of the American Association for Cancer Research, Anaheim, CA, 2005. [**Invited Speaker**]
70. NCI Workshop "Use and misuse of biomarkers as indicators of cancer risk", Bethesda, MD, 2005. [**Invited Speaker**]
71. International Conference on Environmental Mutagens, San Francisco, CA, 2005. [**Invited Speaker, Co-chair**]
72. International Symposium "Molecular Targets for Cancer Prevention", University of Minnesota, Austin, MN, 2005. [**Invited Speaker**]
73. Annual Conference of the Oxygen Club of California, Santa Barbara, CA, 2006. [**Invited Speake**r]
74. Cancer Prevention in the 21st century, Kuala Lumpur, Malaysia, 2006. [**Invited Speaker, Chairperson**]
75. Society of Free Radical Research/ASEAN workshop, Kuching, Sarawak, 2006. [**Invited Speaker**]
76. Frontiers in Polyphenols and Cancer Prevention, Bethesda, MD, 2006. [**Invited Speaker**]
77. Epigenomics conference, San Diego, CA, 2007.
78. 2nd UK Stem Cell Meeting: Epigenetics & Differentiation, London, England, 2007.
79. LPI Diet and Optimum Health Conference, Portland, OR, 2007. [**Organizing Committee, Session Chair**]
80. FASEB Summer Conference on HDACs and Health, Snowmass, CO, 2007. [**Oral Presentation**]
81. American Association of Pharmaceutical Sciences, National Biotechnology Conference, San Diego, CA, 2007. [**Invited Speaker**]
82. 8th International Congress on Integrated Medicine, Tokyo, Japan, 2007. [**Invited Speaker**]
83. "Diet, Epigenetic Events & Cancer Prevention", NIH, Bethesda, MD, 2007. [**Invited Speaker**]
84. 3rd International Conference on Polyphenols and Health, Kyoto, Japan, 2007. [**Invited Speaker, co-organizer**]
85. 38th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, Japan, 2007. [**Invited Speaker, Session Chair**]
86. 2nd International Conference on Translational Cancer Research, Lonavala, India, 2007. [**Invited Speaker, Session Chair**]
87. AICR annual conference, Washington, DC, 2008. [**Invited Speaker**]
88. NCI Translational Science Meeting, Washington, DC, 2008. [**Invited Speaker**]
89. "Dynamic Epigenome in Health and Disease", Bethesda, MD, 2008. [**Invited Speaker**]
90. 4th International Niigata Symposium on Diet and Health, Niigata, Japan, 2008. [**International Advisory Committee, Invited Speaker**]
91. LPI International Conference on Diet and Optimum Health, Portland, OR, 2009. [**Conference co-chair, session chair, speaker**]
92. Society of Free Radical Biology and Medicine (Asia), Pulau Langkawi, Malaysia, 2009. [**Invited Speaker, Session chair, International Scientific Advisory Committee**]
93. FASEB Summer Conference on "HDACs and Reversible Acetylation in Signaling and Disease", Lucca, Italy, 2009. [**Invited Talk**]
94. 4th International Conference on Polyphenols and Health, Harrogate, England, 2009. [**Invited Plenary Lecturer, session co-chair**]

95. American Society of Biochemistry and Molecular Biology, Anaheim, CA, 2010. [**Invited Speaker**]
96. European Environmental Mutagen Society, Oslo, Norway, 2010. [**Invited Speaker**]
97. AACR Frontiers in Cancer Prevention Research, Philadelphia, PA, 2010. [**Invited Speaker**]
98. 2nd International Conference on Nutrition and Physical Activity in Aging, Obesity, and Cancer, Seoul, South Korea, 2011. [**Invited Speaker**]
99. Natural Products and Drug Discovery, King Saud University, Riyadh, Saudi Arabia, 2011. [**Invited Speaker**]
100. Partners in Science Annual Conference, San Diego, CA, 2012. [**Keynote Speaker**]
101. Clinical Epigenetics Society, Homburg, Germany, 2012. [**Keynote Speaker, Session Chair**]
102. Experimental Biology (EB) Conference, San Diego, CA, 2012. [**Invited Speaker**]
103. Keystone Symposium on Nutrition, Epigenetics, and Human Disease, Santa Fe, NM, 2013 [**Invited Speaker**]
104. 10th Nutrition and Health Conference: State of the Science and Clinical Applications, Seattle, WA, 2013. [**Invited Speaker**]
105. LPI International Conference on Diet and Optimum Health, Corvallis, OR, 2013 [**Session organizer and co-chair**]
106. Marabou Symposium: Role of miRNA in Nutrition and Disease, Stockholm, Sweden, 2013 [**Invited Speaker**]
107. Lost Pines Conference "Stem Cells, Epigenetics and Cancer", Smithville, TX, 2013. [**Platform Speaker**]
108. TAMEST: The Academy of Medicine, Engineering & Science of Texas annual conference, Lost Pines, TX, January 2014. [**Protégé**]
109. Energy Balance and Cancer Research, University of Texas MD Anderson Cancer Center, Houston, TX, February 2014. [**Invited Speaker**]
110. Diet, epigenetics and cancer prevention, Gulf Coast Pharmacy Symposium, Corpus Christi, TX, February 2014. [**Invited Speaker**]
111. 20th VFIC Conference, College Station, TX, 2014. [**Keynote Speaker**]
112. 8th Annual Meeting of the Japanese Society for Epigenetics, Tokyo, Japan. 2014. [**Invited Speaker**].
113. 29th Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy, Aspen, Colorado, 2014.
114. AACR Frontiers in Cancer Prevention Research, New Orleans, LA, September 28-30, 2014. [**Invited Speaker**]
115. International Conference of the Korean Society of Molecular and Cellular Biology, Seoul, South Korea, 2014. [**Invited Speaker, symposium co-chair**]
116. 11th International Conference of the Society for Integrative Oncology, Houston, TX, 2014. **[Invited Speaker]**
117. International Conference on Food for Health, Niigata, Japan, 2014. [**Invited Speaker, symposium co-chair**]
118. Cancer Epigenetics: Environmental Influences and Molecular Mechanisms, Houston, TX, 2015. Hosted at the Institute of Biosciences & Technology, Texas A&M Health Science Center. [**Conference organizer and co-chair with Dr. Sharon Dent**]
119. LPI International Conference on Diet and Optimum Health, Corvallis, Oregon, 2015. **[Invited Speaker, symposium co-chair]**
120. Epigenomics of Common Diseases, Wellcome Genome Campus, Hinxton, Cambridge, UK, 2015.
121. Microbiome and Cancer: Environmental Determinants of Disease, Baylor College of Medicine, Houston, TX, 2015. **[Session chair]**
122. Energy Balance and Cancer Research, University of Texas MD Anderson Cancer Center, Houston, TX, January 26, 2016. **[Invited Speaker]**
123. Chromatin, non-coding RNAs and RNAP II regulation in development and disease.

University of Texas, Austin, TX, March 29, 2016.
124. American Association for Cancer Research, New Orleans, LA, April 16-20, 2016.
125. Aspen Cancer Conference, Aspen, CO, July 16-19, 2016.
126. American Association for Cancer Research, Washington, D.C., April 1-5, 2017
127. Aspen Cancer Conference, Aspen, CO, July 15-18, 2017. **[Invited Speaker]**
128. Workshop on Next-gen Epigenomics, Baylor College of Medicine, Houston, TX, November 2, 2017. **[Invited Speaker]**
129. 12th International Conference on Environmental Mutagens, Incheon, S. Korea, November 12-16, 2017. **[Invited Speaker, Session Chair]**
130. 2nd Annual Antimicrobial Resistance and Gut Health Symposium, Rice University, Houston, TX, June 15, 2018.
131. 1st International Conference on Precision Nutrition and Metabolism in Public Health and Medicine, Crete, Greece, September 21-26, 2018. **[Invited Speaker]**
132. 34th Korean Academy of Science and Engineering [KAST] International Symposium, Busan, S. Korea, November 15-16, 2018. **[Invited Speaker]**
133. 11th American Association for Cancer Research-Japan Cancer Association Joint Conference on Breakthroughs in Cancer Research: From Biology to Precision Medicine, Maui, HI, February 8-12, 2019.
134. American Association for Cancer Research (AACR), Atlanta, GA, March 29-April 3, 2019.
135. 14th Annual Texas Conference on Health Disparities, University of North Texas Health Science Center, Fort Worth, Texas, June 6-7, 2019. **[Invited Speaker]**
136. 9th International Conference on Polyphenols and Health, Kobe, Japan. Nov 28 – Dec 5, 2019. **[Invited Speaker]**
137. 10th International Conference on Nutrition and Physical Activity, Bangsaen Thailand, Dec 18-20, 2019. **[Invited Speaker]**
138. American Association for Cancer Research Virtual Annual Meeting, April 24-29, 2020.
139. NCI Translational Advances in Cancer Prevention Agent Development Virtual Meeting, August 27-28, 2020. **[Invited Speaker]**
140. Asia Pacific Nutrigenomics and Nutrigenetics Organization (APNNO) biennial conference, Qingdao, 1-2 December 2020. **[Invited Speaker]**
141. Precision Nutrition: Research Gaps and Opportunities Workshop, NIH Virtual Meeting, January 11-12, 2021.
142. Fox Chase Cancer Center Epigenetics Institute Virtual Symposium: From Nucleic Acids to 3D Genomes to Therapeutics, March 2, 2021.
143. International Molecular Biology and Genetics Conference, Istanbul University, March 26-28, 2021. **[Invited Speaker]**
144. NCI Translational Advances in Cancer Prevention Agent Development Virtual Meeting – Immunomodulatory Agents, September 13-14, 2021. **[Invited Speaker]**
145. 2nd NCI Translational Advances in Cancer Prevention Agent Development Virtual Meeting – Immunomodulatory Agents, September 7-9, 2022.
146. Animal Models for Cancer Interception and Precision Prevention, NCI Workshop, Division of Cancer Prevention and Division of Cancer Biology, National Cancer Institute, October 13-14, 2022.
147. Society for Immunotherapy of Cancer (SITC) Immunoprevention Summit, April 3, 2023.
148. Student Research Symposium, Marshall University, April 8, 2023 [**Keynote speaker**]
149. 3rd Annual Foundations of Cancer Therapeutics, Rice University, Houston, Texas, August 16, 2023. **[Invited Speaker]**
150. Diet and Optimum Health Conference “Precision Health: Living Better, Longer”, Oregon State University, Corvallis, Oregon, September 19-22, 2023
151. 51st International Symposium of the Princess Takamatsu Cancer Research Fund, “Environmental Impacts on Clonal Evolution and Cancer Development”, November 14-16, 2023, Tokyo, Japan. **[Invited Speaker, Session Chair]**

FUNDING (total career awards ~$40 million)

Dashwood, R.H. (PI) 7/90-6/91
Hawai'i Consumer Protection Research Award
"*Chemoprevention of cancer*" $5,000

Dashwood, R.H. (PI) 3/92-2/93
Cancer Research Center of Hawai'i Pilot Project Award
"*Protection by CHL against HCA-DNA adducts*" $11,000

Dashwood, R.H. (PI) 7/92-6/93
American Cancer Society Institutional Grant Pilot Funds
"*Tumor inhibition by CHL in the F344 rat*" $15,000

Dashwood, R.H. (PI) 7/92-6/95
USDA Section 406 Grant
"*Chemopreventive properties of chlorophylls*" $104,000
Dashwood, R.H. (PI) 3/96-2/02
NIH (NCI) R29 CA65525
"*Modulation of colon carcinogenesis by chlorophyllin*" $500,000

Dashwood, R.H. (PI) 7/99-6/02
General Mills Inc.
"*Protection by whole grains against colorectal cancer*" $80,000

Orner, G.A./Dashwood, R.H. (PI/co-PI) 4/1/03-3/31/05
NIH R03 CA097485
"*Combined chemoprevention in β-catenin mutant mice*" $141,500

Orner, G.A./Dashwood, R.H. (PI/co-PI) 9/29/03-8/31/05
NIH R21 CA100608
"*Combined effects of tea plus NSAIDs towards colon cancer*" $419,064

Dashwood, R.H. (PI) 5/10/00-4/30/05
NIH R01 CA80176
"*β-Catenin mutation in PhIP- and IQ-induced colon cancer*" $1,540,597

Dashwood, R.H. (PI) 1/4/04-31/3/09
NIH (NCI) R01 CA65525
"*Modulation of colon carcinogenesis by chlorophyllin*" $1,755,028

Bailey, G.S./Dashwood, R.H. (PI/PD) 4/3/03-3/31/08
NIH (NCI) P01 CA090890
"*Comparative mechanisms of cancer chemoprevention*" $6,180,000

Dashwood, R.H. (PI/PD) 4/11/08-3/31/14
NIH (NCI) P01 CA090890
"*Comparative mechanisms of cancer chemoprevention*" $6,500,000

Dashwood, R.H. (PI) 1/4/08-3/31/13
NIH (NCI) R01 CA122595
"*Dietary HDAC inhibitors in colon cancer prevention*" $1,750,000

Dashwood, R.H. (PI/PD) 10/1/13-12/31/18
Texas A&M University
Chancellor's Research Initiative
"*Center for Epigenetics & Disease Prevention*" $9,147,000

Braam, J., (PI), Dashwood, R (co-PI) 1/1/14-12/31/18
Rice University
USDA AFRI Plant Composition & Stress Tolerance Program
"Daily Cycling of Health Promoting Properties in Diverse Crops" $36,164

Dashwood, R.H., Vilar, E. 5/15/17-12/31/20
NCI PREVENT HHSN26100004
"*Determination of Dosing Regimens of Erlotinib in Combination with Sulindac for Prevention of Colorectal Cancer*" $975,000

Dashwood, R.H., Vilar, E. 7/8/19-1/7/22
NCI PREVENT 75N91019D00021
"Optimization of Dosing Regimens of Sulindac in Combination with Erlotinib for Small Intestinal and Colon Cancer Prevention" $854,290

Dashwood, R.H. 1/1/14-12/31/23
"*Epigenetics and Disease Prevention*" (ACTIVE)
John S. Dunn Foundation (endowed chair – to date) $1,350,000

Dashwood, R.H. (PI/PD) 3/1/18-2/28/24 (ACTIVE)
NCI 2R01 CA122959-06
"*CCAR2 as a Target for Prevention of Colorectal Cancer*" $3,327,543
Role: PI

Sohrabji, F. (PI/PD) 5/1/22-4/30/25 (ACTIVE)
NIH/NINDS/NIA 1 RF1 NS119872
"*Targeting the Gut for Stroke Neuroprotection: IGF-1 Modulation of the Blood-Gut Barrier*" $1,695,842
Role: co-I (5% effort in Years 1-3)

Reddy, S. (PI) 9/30/22-9/29/25 (ACTIVE)
DOD W81XWH-21-ERP-IDA
"*Epigenetic Therapy for Post-traumatic Epilepsy*" $745,304
Role: co-I (4% effort in Year 1)

Dashwood, R.H. (MPI) 4/1/23-3/31/28 (ACTIVE)
1 R01 CA257559-01A1
"*Immunoepigenetic Targeting of MHC Regulators in FAP*" $3,027,814
Role: contact PI, 20% effort (Vilar-Sanchez, MPI/PI)

UNIVERSITY COMMITTEES/SERVICE/INSTRUCTION

1990-1998	ENBI402 "Principles of Environmental Biochemistry", Department of Environmental Biochemistry, University of Hawai'i at Mānoa, Honolulu, HI. (3-credit course, sole instructor for Fall semester).
1991-1998	ENBI402L "Principles of Environmental Biochemistry Lab", Department of Environmental Biochemistry, University of Hawai'i at Mānoa, Honolulu, HI. (2-credit course, sole instructor for Fall semester).

1991-1997	Institutional Animal Care and Use Committee, University of Hawai‘i at Mānoa, Honolulu, HI.
1998-2001	Institutional Animal Care and Use Committee, Oregon State University, Corvallis, OR.
1998-2013	Member of the Graduate Program, Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR.
1998-2013	Member of Graduate Program, Molecular and Cellular Biology, Oregon State University, Corvallis, OR.
1998-2013	Member of the Graduate Program, Biochemistry and Biophysics, Oregon State University, Corvallis, OR.
1998-2013	Graduate Admissions Committee, Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR.
1998-2013	Faculty Search Committees, Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR.
1998-2013	Post-tenure review committees, Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR.
1998-2013	Faculty Advisor, Oregon State University Judo Club, Corvallis, OR.
2002-2013	Director, Cancer Chemoprotection Program, Linus Pauling Institute, Oregon State University, Corvallis, OR.
2003-2013	TOX611 “Testing for Genotoxicity” 4-credit course combining lecture/lab work (sole instructor, course offered annually), Dept. Environmental & Molecular Toxicology, Oregon State University, Corvallis, OR.
2005-2013	PHAR563/MCB563 “Cancer and Chemoprevention” (2-credit course, team-taught every Spring term), School of Pharmacy, Oregon State University, Corvallis, OR.
2009	Scientific Organizing Committee and Conference Co-chair, LPI Diet and Optimum Health Conference, Portland, OR.
2011	Scientific Organizing Committee, and Committee for LPI Prize for Health Research, Diet and Optimum Health Conference, Corvallis, OR.
2013	Scientific Organizing Committee, Session Organizer/Co-chair, and Committee for LPI Prize for Heath Research, Diet and Optimum Health Conference, Corvallis, OR.
2013	College of Pharmacy Promotion and Tenure Committee (*ad hoc*), Oregon State University, Corvallis, OR.
2013	Institutional Animal Care and Use Committee Administrator Search Committee, Oregon State University, Corvallis, OR.

2013-2015	Council of Principal Investigators, Texas A&M University, Bryan, TX.
2013-2020	Distinguished Lecturer Seminar Series (coordinator), Texas A&M College of Medicine, Institute of Biosciences & Technology, Houston, TX.
2013-2019	IBT Intellectual Property Committee, Texas A&M Health, Houston, TX.
2013-present	IBT Tenure & Promotion Committee, Texas A&M Health, Houston, TX.
2013-2015	Texas A&M Health Tenure & Promotion Committee, Houston, TX.
2015	Abcam International Conference “Cancer Epigenetics: Environmental Influences and Molecular Mechanisms”, Organizer and co-Chair, Texas A&M Health – Institute of Biosciences & Technology, Houston, TX.
2015-2016	Postdoctoral Training Subcommittee, Texas A&M University (Chaired by Dr. Emily Wilson, Executive Associate Dean, School of Graduate Studies), Houston and College Station, TX.
2015-2016	Search Advisory Committee for Senior VP for Texas A&M Health and Dean of the College of Medicine, Texas A&M University, Houston, TX.
2015-present	Texas OneGulf Network of Excellence (TONE), University of Houston, Houston, TX.
2015-present	Instructor, MEID618 Medical Grand Rounds, Texas A&M University College of Medicine, College Station, TX.
2016-2018	Texas A&M College of Medicine, Research Advisory Committee, Houston and College Station, TX.
2016-2018	Texas A&M College of Medicine, Faculty Pay-Plan Committee, Houston and College Station, TX [co-chair].
2018-present	Texas A&M College of Medicine, Promotion and Tenure Committee, College Station, Texas.
2018-present	Instructor, Medical Sciences MSCI 601 Contemporary Topics in Advanced Cell Biology, lectures on “Gene expression and epigenetics”, Texas A&M College of Medicine, Houston/College Station, TX.
2019	Chair, Advisory Committee on Administrative Structural Changes for NFSC, Texas A&M University, College Station, TX. (Appointed by Dr. Patrick Stover, Vice Chancellor and Dean for AgriLife Research).
2019	Texas A&M Health Regents Professor Selection Committee.
2019	T&P Committee, Dept. Nutrition and Food Science, Texas A&M University.
2020	Texas A&M College of Medicine Chancellors EDGES Award Selection Committee, Texas A&M University, TX.

2020	T&P Committee, Department of Nutrition, Texas A&M University.
2020	Texas A&M Health VISION360: Research Work Group.
2021	Graduate Student Organization (GSO) Symposium – poster judge.
2021	Course instructor, MSCI 603 Tumor Microenvironment & Cancer Metastasis, lectures on “Cancer epigenetics”, Texas A&M College of Medicine, Houston/College Station TX.
2023-	Dean’s Research Advisory Council (DRAC), Texas A&M University School of Medicine, Houston/College Station TX.
2023-	TAMU School of Medicine Senior Assoc Dean for Res Search Committee.

NON-UNIVERSITY SERVICE

2002-present	Recurring and *ad hoc* NIH grant review panels, including Cancer Etiology (CE), Chemo/Dietary Prevention (CDP), Tumor Microenvironment (TME), NCCAM/NCI/ODS; P01/Subcommittee E reviews; National Advisory Council for Complementary and Alternative Medicine, Washington DC.
2005	Expert Panel and Consultant to Technology Planning and Management, National Toxicology Program, 11th Report on Carcinogens, National Institute of Environmental Health Sciences, Research Triangle Park, NC.
2006-2008	International Scientific Advisor, Universiti Kabangsaan Malaysia Medical Biology Institute (UMBI), Kuala Lumpur, Malaysia.
2011	International Scientific Advisory Board, King Saud University, Riyadh, Saudi Arabia.
2012-2013	International Scientific Advisor, National Agency for the Evaluation of Universities and Research Institutes, Italy.
2014	American Association for Cancer Research (AACR) Special Program for High School Students: *The Conquest of Cancer and the Next Generation of Cancer Researchers.* New Orleans, LA.
2016-present	Advisory Board, The American Medical Professionals Foundation.
2016-present	National Cancer Institute (NCI) PREVENT External Steering Panel.
2016-present	NCI Board of Scientific Advisors, Working Group of External Experts.
2017	Chair, ZRG1 EMNR-A (07) Grant Review Panel.
2018-2022	NIH Cancer Prevention Study Section (CPSS), standing member, chair
2019	Lecture in BIOL 4013 “Topics in Genomics”, Department of Biology, Prairie View A&M University, Prairie View, Texas.

2020 Nutrigenetica e Genomica Nutrizionale Modulo 2. Zoom teleconference with graduate students, Molecular & Applied Biology, Faculty of Sciences, Ancona, Italy.

2021 Trainee Career Development Workshops, The University of Texas MD Anderson Cancer Center, Houston, TX (with Drs. Brown and Hanash).

2022 External Assessor for Promotion to Full Professor at the Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia.

2022 Susan B. Komen Race for the Cure, Texas A&M School of Medicine and Texas A&M Health 5K walk. October 1, 2022, Houston, Texas.

PERSONNEL TRAINED

University of Hawai'i at Mānoa

1990-1994 Nicholas Tachino, undergraduate student.
1991-1995 Dexin Guo, graduate student.
1991-1995 Christina Liew, graduate student.
1993-1995 Shane Yamane, HHMI premedical student.
1994-1999 Meirong Xu, graduate student and Research Assistant.
1995-1996 A. Cecilia Bailey, undergraduate student.
1995-1998 Judith Hernaez, HHMI premedical student.
1996-1998 Christy Taoka, undergraduate student.
1996-1998 Rick Hayashi, HHMI premedical student.
1995-1997 Nahidh Hasaniya, graduate student.
1996-1997 Kristi Youn, undergraduate student.
1996-1998 Azziz Razzuk, graduate student.

Oregon State University

1998-1999 Gilberto Santa-Rios, postdoctoral research associate.
1998-1999 Rongliang Chen, postdoctoral research associate.
1999-2003 Carmen Blum, graduate student.
1999 Maria Izquierdo-Pulido, sabbatical professor, University of Barcelona.
1999 Arthur T. Fong, sabbatical visitor.
2000 Yu Zhen, graduate student on laboratory rotation.
2000 R. Shen, graduate student on laboratory rotation.
2000 Adams Amantana, graduate student on laboratory rotation.
2000 Cynthia Provost, undergraduate summer rotation.
2001 S-Y. Wu, undergraduate laboratory rotation.
2001 Brian Dixon, graduate student laboratory rotation.
2000-2008 Gayle Orner, postdoctoral research associate.
2000-2002 Mohamed Al-Fageeh, graduate student.
2000-2003 G. Darío Díaz, postdoctoral research associate.
2001-2005 Qingjie Li, postdoctoral research associate.
2001-2005 Melinda Myzak, graduate student.
2002-2003 Xiaoying Zhen, student rotation.
2002-2003 Tomoko Tanaka, student rotation.
2002-2013 David Yu, Laboratory Manager, Cancer Chemoprotection Program.
2002-2013 Wan Mohaiza Dashwood, Senior Faculty Research Assistant.
2002-2004 Orianna Carter, postdoctoral research associate.

2002-2003 Sun Yoon, sabbatical professor, Yonsei University, South Korea.
2002-2003 Kwon Daejoon, postdoctoral research associate.
2003-2004 Nico Dissmeyer, graduate student laboratory rotation.
2004-2007 Nihal Gooneratne, graduate student laboratory rotation.
2004-2013 Rong Wang, postdoctoral research associate.
2005-2008 Barbara Delage, postdoctoral research associate.
2005-2010 Chris Larsen, graduate student.
2005-2009 Kate Cleveland, graduate student.
2006-2010 Hui Nian, graduate student.
2007-2008 Lee Kee-Myung, sabbatical visitor, South Korea.
2007-2009 Korakod Chimploy, postdoctoral research associate.
2007-2008 Yasmin Anum, visiting professor, UKM-Malaysia.
2007-2008 Judith Hernaez, postdoctoral research associate.
2009-2010 Khaled Al Alwani, internal medicine, volunteer.
2009-2013 Praveen Rajendran, postdoctoral research associate.
2010 Andrew Quest, sabbatical professor, University of Santiago, Chile.
2010-2011 Lydia Petell, Research Assistant.
2011-2012 Mansi Parasramka, postdoctoral scholar.
2011-2013 Yuki Kang, postdoctoral scholar.
2012-2013 Christiane Löhr, sabbatical professor, Oregon State University.
2012 Hiroshi Nishida, sabbatical professor, Niigata University, Japan.

Texas A&M Health/School of Medicine

2012-2019 Gavin Johnson, graduate student (thesis chair).
2012-2019 Ying-Shiuan Chen, graduate student (thesis chair) – now at MD Anderson.
2013-2015 Ashley Perkins, graduate student (thesis co-chair) – now at MD Anderson.
2013-2015 Eunah Kim, postdoctoral scholar.
2013- Praveen Rajendran, Associate Professor.
2014-2016 Li Li, Research Assistant.
2014-2014 Lalita Singh, Research Assistant.
2015-2016 Furkan Ertem, M.D., postdoctoral scholar.
2015-2016 Lindsey Chew, Laboratory Attendant.
2015-2016 Ahsan Khan, Research Technician.
2016-2018 Adaobi Okonkwo, Research Assistant.
2017,2018 Stephanie Hammons, undergraduate summer student.
2017-2020 Ahmet Ulusan, M.D., postdoctoral scholar.
2016-2021 Mutian Zhang, bioinformatics PhD graduate student (thesis co-chair).
2018 Max Ramsaroop, high school volunteer.
2018 Emma Solis, student assistant.
2018- Sabeeta Kapoor, Research Assistant/Associate/Postdoctoral Scholar.
2018-2019 Omer Yavuz, M.D., Research Assistant.
2018-2020 Trace Alexander Gustafson, Research Assistant.
2019- Nivedhitha Mohan, Ph.D. Medical Sciences, graduate student (thesis chair).
2019-2020 Elisabetta Damiani, Ph.D., visiting scientist (Ancona, Italy)
2019-2020 Dong Han, Ph.D., visiting scholar, Harbin Medical University, China.
2019-2021 Yunus Demirhan, M.D., postdoctoral scholar.
2019- Jorge Tovar Perez, Ph.D. Medical Sciences, graduate student (thesis chair).
2018-2020 Yue Yin, bioinformatics, Ph.D. graduate student (thesis co-chair).
2020 Shamee Bhattacharjee, Ph.D., visiting scholar, W. Bengal State University.
2020 Linh Huynh, Ph.D. Medical Sciences, lab rotation.
2020- Ahmed Muhsin, Ph.D. Medical Sciences, graduate student (thesis chair).
2020-2021 Melek Demirhan. M.D., Laboratory Researcher.

2019-2022 Shilan Zhang, Ph.D. student and CSC scholar, Central South University, China.
2021-2022 Chakrapani Tripathi, Ph.D., postdoctoral scholar.
2021-2022 Alessandro Shapiro, laboratory technician.
2021- Sultan Abda Neja, Ph.D., postdoctoral scholar.
2022 Christopher Alejandro, undergraduate summer student.
2022-2023 Agata Binienda, grad student visiting fellow, Medical University of Lodz, Poland.

Others (as a member of the graduate thesis committee or as an external examiner*)

1991-1995 Phillip Bridges, Department of Animal Sciences, University of Hawai'i at Mānoa.
1992-1997 Lin Gao, Dept. Food Science and Human Nutrition, University of Hawai'i at Mānoa.
1993-1998 Ravi Jasuja, Department of Chemistry, University of Hawai'i at Mānoa.
2000-2003 Niall Tebbutt, School of Medicine, University of Melbourne, Australia*.
2001-2005 Yu Zhen, Department on Environmental and Molecular Toxicology, OSU.
2001-2003 Susan Tilton, Department on Environmental and Molecular Toxicology, OSU.
2001-2007 Amy Skinner, Oregon Health & Science University, Portland, OR.
2005-2009 Anna Hsu, Department of Nutrition, Oregon State University.
2005-2009 David Castro, Department on Environmental and Molecular Toxicology, OSU.
2005-2009 Chan Kok Meng, Universiti Kabangsaan Malaysia, Kuala Lumpur, Malaysia*.
2004-2009 Hyo Sang Jang, Department of Biochemistry and Biophysics, OSU.
2006-2010 Reza Mokhtari, University of Toronto, Canada*.
2010-2013 Yan Campbell, Department of Biochemistry and Biophysics, OSU.
2009-2013 John Clarke, Department of Nutrition and Exercise Science, OSU
2011-2015 Lauren Atwell, Department of Nutrition and Exercise Science, OSU.
2011-2015 Greg Watson, Department of Nutrition and Exercise Science, OSU.
2015-2018 Wenjiao Li, Institute of Biosciences & Technology, Texas A&M University.
2016-2018 Changhong Yun, University of Houston, College of Pharmacy.
2016-2018 Emma Spencer, Dept. Pathology, University of Otago, Christchurch, New Zealand*.
2016-2021 Yuanning Zheng, Dept. Mol Cellular Medicine, Texas A&M College of Medicine.
2020-2021 Sarah Chau, Biotechnology graduate student, Texas A&M University.
2020- Xian Wang, Dept. Nutrition, Texas A&M, graduate thesis committee member.

Others (undergraduates on laboratory rotation)

2002 Darren Leva (microbiology).
2003-2004 Robert Weston (chemistry).
2004-2007 Maryam Moussaoui (bioengineering).
2004-2005 Violet Depoe (animal sciences).
2004 Roland Corden (animal sciences).
2004-2006 Nihal Gooneratne (biochemistry and biophysics).
2004-2005 Carol Bennett (biology).
2005-2010 Ahson Saeed (bioengineering).
2005-2007 Carianne Stearns (biology).
2005-2006 Megan Tinsley (biology)
2005 Oanh Ngo (biology)
2005-2006 Adrienne Strubb (biology).
2006-2008 Daniel Schwartz (bioengineering).
2006-2007 Laura Magana (bioengineering).
2006-2007 Britnee Southland (animal sciences).
2006 Renee Cardinwaux (graphics).
2007-2009 Brodie Miles (microbiology).
2007-2008 Grant Blakely (bioengineering).
2009-2010 Carly Bradley (biology).

2009-2010 Harsukh Singh (biology).
2009-2012 Bradyn Wuth (engineering).
2010-2011 Katherine Tai (biochemistry and biophysics).
2010-2013 Hassaan Saeed (bioengineering).
2011-2012 Amir Abdelli (bioengineering).
2011-2013 Ashley Pearson (biology).
2012 Raquel Vaz (HHMI-Brazil).
2012-2013 Matthew Kaiser (HHMI).
2012-2013 Jacquelynn Allen (biochemistry).
2012-2013 Cameron Mastin (biology).
2012-2013 Carlos Falcon (bioengineering).
2014 Tasneem Mahmood (psychology)
2015 Rodrigo Jaimes (Biology) University of Texas Pan-America.
2019 Zachrieh Alhaj, undergraduate summer research scholar.
2019 Takato Inoue, medical student summer visitor (Chiba School of Medicine).

WEBSITES

h-index: Scholar

ORCiD: 0003-0351-4034

Ranking: top-scholars-worldwide/

DECLARATION

This document was accurate at the time of submission and there are no competing interests.